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Abstract
Background: During the last decades, health-related quality of life (HRQoL)
measurement has become an important outcome in treatment studies and in health policy
decisions.  Inflammatory bowel diseases (IBDs) are chronic gastrointestinal diseases of
unknown aetiology.  Symptoms of IBD can be bothersome and sometimes painful.  In
earlier studies, impairment of health-related quality of life was evident in IBD, especially
when the disease was active.  In addition to the physical symptoms, the mental state and
social support were also found to affect HRQoL.  Data about the impact of demographic
characteristics or comorbidity of the patients on HRQoL are partly controversial.
HRQoL can be measured by using generic or disease-specific tools. Generic
instruments can be used for comparing health status among patients in different health
states, conditions and diseases.  However, these instruments do not focus specifically on
the issues relevant to a particular disease, as they were developed for general populations.
Disease-specific tools may be more responsive to changes within a specific condition.
The disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ) used in this
study has been utilized in many earlier surveys with smaller patient samples.  In contrast,
data about the feasibility of using the generic 15D tool in IBD are scarce.  The aims of this
study were to compare HRQoL, the frequency of symptoms, and the arrangement of
therapy of Finnish IBD patients with those of European IBD patients.  The health-related
quality of life in Finnish IBD patients using both the IBDQ and 15D instruments was also
examined.  Furthermore, comorbidity of IBD patients and influence of comorbidity on
HRQoL were evaluated.
Patients and methods: The study questionnaire was mailed to 3852 adult (over 18 years
of age) members of the Crohn’s and Colitis Association of Finland in September 2006,
and to an additional 1490 adult patients selected from the Social Insurance Institution
register of Finland in February 2008.  In study I, the differences in the diagnosis of IBD,
current and previous therapies, frequency of IBD symptoms, and impact of symptoms on
HRQoL of Finnish patients were compared with those of patients who participated in an
earlier European study that comprised 5576 IBD patients from seven countries.  Study II
evaluated the disease-specific IBDQ scores in Finnish IBD patients.  In study III, the
generic 15D scores of IBD patients were compared with scores of a gender and age
matched general population sample obtained from two national health surveys.  Moreover,
the 15D scores were compared with the IBDQ scores to evaluate the feasibility of 15D as
a  HRQoL  tool  for  IBD.   In  study  IV,  two  age,  gender,  and  hospital  district  matched
control subjects for each participant were selected from the Social Insurance Institution
register for a comparison of comorbidity between IBD patients and the general population.
Data  of  other  chronic  diseases  were  obtained  from  the  Social  Insurance  Institution’s
reimbursement register.
Results: The response rate was 57%.  Of these patients, 37% reported that they suffered
from disturbing IBD symptoms weekly.  In 17% of the patients, the symptoms greatly
affected their ability to enjoy leisure activities, and 14% stated that these symtoms greatly
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affected  their  capacity  to  work.   Despite  that,  the  great  majority  (93%)  of  patients
expressed satisfaction with their current treatment and only 1.4% were very dissatisfied.
43% of the Crohn’s disease (CD) patients had undergone surgery, whereas the
percentage was 12% for ulcerative colitis (UC).  Rates of surgery were lower than in the
previous European survey. Over a quarter of operated patients reported postoperative
complications in both surveys.
The IBDQ scores ranged from 43 to 224, whereas the possible range is 32 to 224.  The
mean total score was 163, and disease activity was the most strongly correlated factor with
HRQoL.   Older  age,  comorbid  diseases,  and  female  gender  were  also  related  to
impairment of HRQoL.  Lower HRQoL scores were also seen in newly-diagnosed patients
and in those with a history of surgery, especially after stoma or ileal pouch-anal
anastomosis (IPAA) operation.
The range of 15D scores was 0.30-1.00, with a mean of 0.87.  As found with the
IBDQ, disease activity was strongly correlated with the score, but not even those who
reported infrequent symptoms could reach the 15D level of the control group.  Sex of the
patient or disease type had no significant impact on the score, but older age and a history
of surgery were related to lower scores.  Newly-diagnosed patients and patients with a
long-lasting disease had lower scores than average after adjusting for age.  The 15D tool
appeared to be a feasible and easy-to-use instrument to assess HRQoL for IBD, and the
15D scores were strongly correlated with the IBDQ scores.
Comorbidity with other chronic diseases was found in 29% of IBD patients.
Connective tissue diseases, asthma and chronic obstructive pulmonary diseases, pernicious
anaemia, and coronary heart disease were significantly increased among patients with
IBD.  Females with IBD appeared to be especially at increased risk of CHD with a 1.6-
fold prevalence to that of their peers (p=0.014), and those who reported weekly symptoms
had a higher risk of having other chronic diseases in addition to IBD.  Comorbidity
impaired HRQoL as measured by using both the generic and disease-specific tools.
Conclusions: IBD had a considerable impact of the daily life of the patients.  Symptoms
that affected leisure activities, work, and HRQoL were common in IBD.  Disease activity
was the most important factor related to HRQoL, and older age, comorbidity, and female
sex also impaired HRQoL.  Newly-diagnosed patients and those with a history of surgery,
especially for stoma or IPAA operation, had low HRQoL scores.
The risk for many other chronic diseases, such as CHD, connective tissue diseases,
asthma and chronic obstructive pulmonary diseases was increased with IBD. The
increased prevalence of CHD in IBD predisposes to more efficacious management of
other possible underlying cardiovascular risk factors in addition to the inflammatory
activity of IBD.  The increased risk for preterm cardiovascular disease should be borne in
mind especially in females.
The burden of IBD symptoms on various aspects of general well-being was most
marked in those patients with the active disease.  However, patients with inactive disease
may also have impaired HRQoL, and the impact of the chronic disease on their daily lives
may be remarkable.  An understanding of predictors of HRQoL will help to recognise
patients needing special support.
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1 Introduction
The primary aim of medical care is to improve or maintain the overall functional capacity
and the general health of patients.  The success of a treatment has been traditionally
measured by biomedical or clinical end points such as survival, response rates, time to
progression, relapse or treatment failure, mortality, morbidity and duration of hospital stay
(Sajid 2008).
Edwards and Truelove were probably the first to include a measurement of “invalidism
being experienced by the surviving members” in their study on the course and prognosis
of  ulcerative  colitis.   In  their  study,  88%  of  the  patients  reported  living  entirely  or
essentially normal lives in spite of their disease and the prerequisite hospital visits
(Edwards and Truelove 1963).  During the last decades, the measurement of health-related
quality of life (HRQoL) has become an important outcome in treatment studies in addition
to being a factor in health policy decisions (Garratt et al 2002).  Chronic diseases, which
include inflammatory bowel disease (IBD), were found to have a marked impact on
HRQoL, especially when frequent symptoms or complications exist (Irvine et al 1994,
Mili et al 2003, Wändell 2005).
Although numerous instruments for HRQoL evaluation have been developed, there is
no gold standard for HRQoL.  The World Health Organization (WHO) defined HRQoL
as:
“Individuals’ perception of their position in life in the context of the culture and value
systems in which they live and in relation to their goals, expectations, standards and
concerns.  It is a broad ranging concept affected in a complex way by the person's
physical health, psychological state, level of independence, social relationships,
personal beliefs and their relationship to salient features of their environment”.
WHO 1997
Having a chronic disease influences HRQoL in many ways.  IBDs are chronic diseases
that are characterized by remission and relapse periods.  Patients often have bothersome
symptoms that affect their daily lives, and there is also a risk of having to undergo surgery
or having a malignancy.  The HRQoL of IBD patients has been surveyed earlier in many
studies.  However, little is known about the overall quality of life of Finnish IBD patients,
or about the impacts of IBD symptoms, comorbidities and given therapies on their  daily
lives.
This thesis investigated the HRQoL for a large cohort of Finnish IBD patients by using
a disease-specific inflammatory bowel disease questionnaire (IBDQ) and a generic 15D
questionnaire.  The former is used in many earlier IBD studies throughout the world, but
to the best of the author’s knowledge the latter has not been used in specific IBD studies
before.  Another aim was to evaluate factors that affect HRQoL in patients with IBD, and
to survey comorbidities and their impacts on HRQoL of IBD patients.
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2 Review of the literature
Inflammatory bowel diseases, namely Crohn’s disease (CD) and ulcerative colitis (UC),
are chronic inflammatory diseases of the gastrointestinal track. The first description of
IBD as a separate entity from epidemic dysentery was made by the British physician
Samuel Wilks in 1859.  In the same year, he also described a case report entitled “Morbid
appearances in the intestine of Miss Bankes” in the London Medical Gazette, a case
resembling ileocaecal CD (Kirsner 1988). CD was formerly called regional enteritis or
terminal ileitis, and is named after Dr. Burrill B. Crohn, who described the disease along
with his colleagues Ginzburg and Oppenheimer in 1932 (Crohn et al 1932).
2.1 Aetiopathogenesis
2.1.1 Aetiology and pathogenesis
Although the knowledge of immunological mechanisms has increased during the past
years, the aetiology and pathogenesis of IBD remains incompletely understood.  The most
widely accepted hypothesis is that the damage to the bowel mucosa occurs as a result of a
dysregulated immune response to multiple mucosal antigens comprised within the
constituents of the normal intestinal flora (Baumgart and Carding 2007, Brown and Mayer
2007). Dysbiosis of mucosa-associated intestinal microbiota is one of the major
characteristics in IBD (Ott et al 2004, Tamboli et al 2004, Manichahn et al 2006, Rehman
et al 2010) but its contribution to disease pathogenesis has been controversial (Ott et al
2004, Gophna et al 2006, Ott et al 2008, Nell et al 2010).
Intestinal microvascular ischaemia has also been suggested to play a role in the
pathogenesis of IBD (Wakefield et al 1989, Maconi et al 1996, van Oostayen et al 1994).
An inverse association between appendectomy and UC has been reported in many studies,
whereas appendectomy has a positive correlation with CD. The mechanism is unknown,
but the appendix may have a role in the mucosal immune system (Koutroubakis and
Vlachonikolis 2000).
2.1.2 Genetics
A significant proportion of IBD patients have a positive family history in up to 22% of
cases in population-based studies (Gaya et al 2006, Ben-Horin et al 2009).  Moreover, for
those IBD patients diagnosed at younger than 20 years of age, over one-third were found
to have other family members with IBD (Farmer 1989).  The onset of disease in familial
IBD cases often occurs at younger age than in sporadic cases (Yang et al 1993, Polito et al
1996).
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In recent years, advances on genome-wide association studies and linkage analysis
methods have aided the understanding of the genetics of IBD, as more than 30 IBD
susceptible loci have been found (Ishihara et al 2009).  The findings indicate the polygenic
aetiology of CD and UC (Gaya et al 2006). The first IBD susceptible gene found was the
nucleotide oligomerisation domain 2 (NOD2).  This was previously known as the caspase
activated recruitment domain protein 15 (CARD15) and is located in chromosome 16
(Hampe et al 2001, Hugot et al 2001, Ogura et al 2001).  NOD2/CARD15 mutation has
been associated mainly with CD, especially when ileal involvement, fistulizing or
stricturing disease phenotype, and/or familially occurring CD are present (Ahmad et al
2002, Lesage et al 2002, Radlmayr et al 2002, Heliö et al 2003).  In the initial study by
Hugot et al,  allelic  variants  of  the  CARD15  gene  were  found  to  be  present  in  43%  of
patients with CD (Hugot et al 1996).  However, since that study evidence of ethnic
variation in the contribution of the gene has become evident.  In Northern Europe, Asia,
Ireland and Scotland the contribution of the gene to CD susceptibility is much lower than
elsewhere in Europe (Heliö et al 2003, Gaya et al 2006), and in Finland the allelic
frequency in CD patients is only about 5% (Heliö et al 2003).
Recently, linkage analyses have drawn the attention of researchers to the IBD3 region
(major histocompatibility complex) of chromosome 6p, the IBD5 locus in chromosome 5
(5q31-33) and CARD4 gene in chromosome 7 (7p14) (Gaya et al 2006).
2.1.3 Environmental factors
Genetics alone is insufficient to explain the development of IBD.  Several environmental
triggers have been investigated, and no single factor has been found to be responsible for
the  development  of  IBD.  Agents  that  break  the  mucosal  barrier  of  the  intestine  such  as
nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and viral and bacterial
infections, have been identified as triggers of IBD (Mayer 2010).  Smoking is a risk factor
for the development of CD, and is associated with a more active disease, whereas in UC,
the effect of smoking seems to be protective (Calkins 1989, Russel et al 1998).  Stress is
not clearly linked to the development of IBD, but it can alter the host immune response or
gut flora thus predisposing the subject to the disease (Hunter 2008, Levenstein 2008).  A
high linoleic acid intake has recently been associated with increased risk of UC.  An
estimated 30% of cases could be attributed to having dietary intakes higher than the lowest
quartile of linoleic acid intake (The IBD in EPIC Study Investigators 2009).  Moreover,
vitamin D3 has very recently been shown to modify T-cell proliferation and increase IL-6
levels in CD patients (Bendix-Struve et al 2010), and vitamin D3 levels  have been found
to be lower  in CD patients than in controls (McCarthy et al 2005).
2.1.4 Immune response
The mechanisms responsible of maintaining oral tolerance to microbes and food-derived
antigens in a healthy gut are still incompletely understood.  The response of a defective
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mucosal immune system to mucosal microflora and other luminal antigens in IBD lead to
damage and increased permeability of the bowel mucosa (Baumgart and Carding 2007).
There are two basic components to the immune response: the innate and the adaptive
response. The innate immunity, which is responsible for the early initial immune response,
is more primitive and lacks the specificity and the ability to augment responses upon
reinfection.  In the intestine, the innate immunity includes the epithelial barrier and
phagocytic cells within the lamina propria (macrophages, dendritic cells, and neutrophils).
The incidence of IBD is increased in patients with genetic defects in the innate
immunology (Dieckgraefe and Korzenik 2002).  The expression of -defensins is needed
for prevention of microbial invasion through the intestinal mucosa, and in ileal CD it is
lower than in CD patients with unaffected ileum or the ileum of healthy controls
(Wehkamp et al 2007).
The adaptive immunity, although slower than the innate immunity, complements the
immune system and is characterized by specificity and memory.  The adaptive immune
system is mostly based on T- and B lymphocytes that express antigen receptors on their
surfaces (Mayer 2010).  Current evidence indicates that defective T-cell apoptosis and
impairment of intestinal epithelial barrier play crucial roles in the pathogenesis of IBD
(Dignass et al 2004).  Without the appropriate control of T-cell proliferation and death
during an immune response, accumulation of T-cells and intestinal inflammation may
occur.
Recently, proinflammatory Th17 cytokines, such as IL-17, IL-22, and IL-23, have
been found to play crucial roles in intestinal protection and homeostasis by recruiting
neutrophils and macrophages at infected tissues (Shen and Durum 2010).
Toll-like receptors (TLRs) recognise specific microbial components and trigger innate
and adaptive antimicrobial responses.  In IBD, changes in TLR expression have been
found, which leads to the impairment of the elimination of microbes, and also to chronic
inflammation (Baumgart and Carding 2007).
2.2 Epidemiology
The peak incidence of IBD occurs between 16-26 years of age (Vind et  al 2006) and in
CD, a slight predominance of females can be seen (Loftus 2004, Vind et al 2006).
In many epidemiological studies, a north-south gradient with higher incidence of IBD
in northern countries and even within southern and northern parts of the United States,
exists (Loftus 2004, Sonnenberg et al 1991).  A Norwegian study reported that the
incidence of IBD was higher in municipalities inhabited by people with the highest level
of education and in urban municipalities (Aamodt et al 2008).  There are also ethnic
differences in incidence and prevalence of IBD.  The incidence of UC is 3 to 5 times
higher in Jews than in non-Jews, which implicates their genetic susceptibility to the
disease.  Ashkenazi Jews in Israel have a lower incidence of UC than those living in the
United States or Northern Europe, which suggests that environmental factors also play an
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important  role  in  the  pathogenesis  of  IBD  (Niv et al 2000).   In  North  America,  the
prevalence of CD is higher in white individuals and African-American individuals than in
Hispanic  or  Asian  people,  and  differences  in  disease  location  and  extraintestinal  disease
complications between ethnic groups have also been observed (Kurata et al 1992, Nguyen
et al 2006).  In South Africa, the incidence of IBD in the coloured population is markedly
lower than in whites (Wright et al 1986).  Although IBD incidence in Western countries
shows stabilization or decline, rates of IBD continue to rise in many Asian countries (Al-
Ghamdi et al 2004, Leong et al 2004, Asakura et al 2009).
A population-based study conducted in Olmsted County, Minnesota, found that the
incidence rates of CD and UC increased after 1940, but have remained stable since the
1980’s.  Today, the prevalence of UC is decreasing, whereas that of CD is increasing due
to earlier age of onset and low mortality (Loftus et al 2007).  Another population-based
study reported, that the incidence of CD in Sweden increased until the 1990’s, but has
been decreasing since 1996 (Lapidus 2006).  In Denmark, increasing incidences of both
UC and CD have been observed (Vind et al 2006).  A recently published study of IBD
incidence in Pirkanmaa county in Finland in 1986-1999 showed an increase of annual
incidence of IBD from 19.5 to 29.2 per 100 000 inhabitants with the increase observed for
both UC and CD.  The prevalences were 291/100 000 for UC and 124/100 000 for CD
(Manninen et al 2010).  The highest prevalence of CD reported, 319/100 000, was in the
province of Nova Scotia, Canada (Bernstein et al 2006).  The incidence of IBD in children
is increasing in many countries (Kolek et al 2004, Turunen et al 2006, Malaty et al 2010).
In 2009, the register of the Social Insurance Institution in Finland comprised 33 445
individuals who were eligible for reimbursement for their IBD medication, which equals a
prevalence of about 620/100 000 (Statistical Yearbook of the Social Insurance Institution
2010).
2.3 Diagnosis and natural history of IBD
No single specific test for diagnosing IBD is available.  Lennard-Jones and Shivananda
have defined widely accepted macroscopic and microscopic criteria for diagnosing IBD
(Lennard-Jones and Shivananda 1997). Clinical evaluation with a combination of
endoscopic, histological, biochemical and sometimes radiological investigations are
needed to confirm the diagnosis (Van Assche et al 2010a). A Working Party of the 2005
Montreal  World  Congress  of  Gastroenterology  introduced  a  classification  of  IBD,  and
provided recommendations for clinical classification in practice (Silverberg et al 2005).
The classification for CD was a modification of the earlier Vienna classification (Gasche
et al 1998).  UC and CD can most often be differentiated by their clinical characteristics.
The term “colitis yet to be classified” describes a situation where definitive distinction
between UC, CD and other causes of colitis cannot be made after appropriate diagnostic
tests (Satsangi et al 2006). “Indeterminate colitis” refers to pathological-anatomical
diagnosis, which is made usually from a colectomy specimen that has overlapping features
of both UC and CD (Price 1978, Satsangi et al 2006).  In five years follow-up, change of
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diagnosis occurred in 9% of the patients originally classified as UC, CD, unclassified
colitis or possible IBD.  A change to non-IBD was more frequent than change between
UC and CD (Henriksen et al 2006b).
2.3.1 Clinical presentation
The  most  pronounced  symptoms  of  UC  are  loose  stools  or  diarrhoea,  which  are  almost
invariably associated with rectal bleeding (Lennard-Jones and Shivananda 1997, Stange et
al 2008).  Patients with the active disease also present with rectal urgency, tenesmi,
passage of mucopurulent exudates, crampy abdominal pain, and nocturnal and
postprandial defaecation.  Constipation or feeling of incomplete evacuation, usually with
visible blood in the stools, can also occur in active colitis (Rao et al 1988).  The onset of
UC is often insidious.  Systemic symptoms, such as weight loss, fever, tachycardia, nausea
and vomiting, are features of severe attack (Baumgart and Sandborn 2007).
Clinical presentation and symptoms in CD depend on disease severity and location.
Chronic diarrhoea is the most common symptom that occurs in up to 85% of patients
(Nikolaus and Schreiber 2007).  Abdominal pain presents in 70% and weight loss in 60%
of patients before diagnosis.  Blood and mucus in the stools are found less frequently than
in UC, but are reported for between 40 and 50% of sufferers (Lennard-Jones and
Shivananda 1997).  In population-based studies, fistulas occur in about 20% of CD
patients and the cumulative incidence increases with duration of the disease (Schwartz et
al 2002).
As UC is limited to the colon, CD can involve any part of the gastrointestinal tract,
most often the ileum and the colon, however (Cosnes et al 2002, Silverberg et al 2005,
Stange et al 2008).  UC affects the rectum and a variable extent of the colon in continuity.
The Montreal Working Group suggests a classification of UC into proctitis, left-sided
colitis and extensive colitis (beyond the splenic flexure) and also takes into account
disease behaviour and age at diagnosis in addition to disease location (Silverberg et al
2005).  In a US study, 28% of the patients had proctitis, 25% left-sided colitis and 47%
extensive colitis (Loftus et al 2000).   The  extent  of  UC influences  the  management  and
frequency of surveillance of patients (Katsanos et al 2007, Stange et al 2008).  However,
the  extent  of  the  disease  is  not  a  fixed  parameter  and  can  change  over  time.   Proximal
extension of UC has been observed in up to 53% of patients with a left-sided UC or
proctitis (Langholtz et al 1996, Moum et al 1999).  Infrequently, appendiceal skip lesions
and backwash ileitis are seen in UC (Ladefoged et al 2005, Haskell et al 2005).
2.3.2 Clinical course
IBD  primarily  presents  at  late  adolescence  or  early  adulthood  and  affects  both  sexes
(Loftus 2004, Stange et al 2008).  The disease is characterized by chronic inflammation
and typically has a relapsing and remitting course (Friedman and Blumberg 2008).
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In CD, 80% of the patients will experience at least one relapse during a 10-year
follow-up (Wolters et al 2006a) and 60% of the patients will develop a stricturing or
penetrating complication of the disease in the long run (Cosnes et al 2002).  Patients with
small bowel involvement are especially prone to stricturing complications and those with
perianal lesions to penetrating complications (Cosnes et al 2002). Predictors of
progressive disease are age younger than 40 years, perianal disease, and the need for
steroids (Beaugerie et al 2006).
In UC, a relapsing disease has been reported in over 80% of patients, but some other
studies found that nearly half (48%) had stayed in remission for years (Solberg et al
2009).   Figure  1  shows  the  different  course  patterns  of  UC  (Solberg et al 2009). A
decrease in symptoms has been observed in 59% of patients in a five year follow-up
(Henriksen et al 2006a), and in a large Norwegian study, 40% of UC patients had been in
remission for the last five years of a 10-year follow-up after diagnosis (Solberg et al
2007).
No significant increase in mortality has been observed for UC, whereas for CD, there
is excess mortality from gastrointestinal causes and, in some studies, from cancer (Masala
et al 2004, Wolters et al 2006b, Höie et al 2007, Solberg et al 2009).
Figure 1. Different courses of ulcerative colitis in ten years follow-up.
Figure from: Solberg et al. Scand J Gastroenterol  2009;44:431-440.
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2.3.3 Extraintestinal manifestations of IBD
The most important extraintestinal manifestations of IBD include arthropathies (peripheral
and axial), cutaneous manifestations (erythema nodosum, pyoderma gangrenosum,
Sweet’s syndrome), ocular manifestations (uveitis, episcleritis) and hepatobiliary
manifestations (primary sclerosing cholangitis).  Peripheral arthritis, erythema nodosum,
oral aphthous ulcers and episcleritis are related to IBD activity, whereas pyoderma
gangrenosum, uveitis, spondylathropathy and primary sclerosing cholangitis are
independent of it (Van Assche et al 2010b, Biancone et al 2008).
The most common extraintestinal manifestations are inflammatory arthropathies with a
prevalence of between 10 to 20%.  Radiological evidence of sacroilitis can be detected in
up to 25% of the patients, but clinical ankylosing spondylitis, as defined by accepted
criteria, can be diagnosed in 3 to 10% (Bernstein et al 2001a, De Vos 2004).  Non-
inflammatory joint pain, i.e. joint pain without underlying arthrosis or arthritis,  was
reported  by  16%  of  IBD  patients  (22%  in  CD)  with  no  association  to  the  extent  of  the
disease, medication, surgery or markers of systemic inflammation (Palm et al 2005).
Primary sclerosing cholangitis (PSC) markedly increases risk for cholangiocarcinoma and
colon cancer (MacFaul and Chapman 2004).  The incidence of PSC is up to 16 in 100 000
in  the  general  population,  and  over  three  quarters  of  PSC  patients  have  also  been
diagnosed with IBD (Lindqvist et al 2010).  On the other hand, PSC affects up to 5% of
IBD patients (Saich and Chapman 2008).  Currently, PSC is the most common indication
for liver transplantation in the Nordic countries (www.scandiatransplant.org).
IBD has also been found to be associated with increased risk of osteoporosis and
osteopenia, nephrolithiasis, amyloidosis, idiopathic pancreatitis, myocarditis and
pleuropericarditis (Danese et al 2005).
2.3.4 Endoscopic, radiological and laboratory examinations
2.3.4.1 Endoscopy
Ileocolonoscopy, and systematic mucosal biopsies from each anatomic segment should be
performed  to  establish  the  diagnosis  of  IBD.   A  minimum  of  two  biopsy  samples  from
each of five sites of the colon and the ileum should be obtained for a reliable diagnosis of
IBD (Van Assche et al 2010a).
Endoscopic appearance is useful in differentiating UC from CD.  UC typically presents
with continuous, uniform inflammation that extends proximally from the rectum. The
inflammation is normally limited to the colon, but occasionally a “backwash” ileitis occurs
in total colitis.  Rectal sparing has been described in children prior to treatment, and in
adults following topical or systemic therapy for UC (Kim et al 1999, Rajwal et al 2004).
The endoscopic features of CD are discontinuous involvement, anal lesions and
cobblestone appearance of the ileum. The inflammation can involve any part of the
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gastrointestinal tract, and the rectum can be spared.  Small, deep aphthous lesions or
longitudinal, polygonal ulcerations occur (Nikolaus and Schreiber 2007).
Colonoscopy is used for diagnosis, and also for follow-up of IBD patients.
Chromoendoscopy improves detection of pre-malignant and malignant mucosal lesions
(Thorlacius and Toth 2007).  Oesophagogastroduodenoscopy (OEGD) is recommended
for both CD and UC patients with upper gastrointestinal symptoms.  OEGD can be useful
in patients with unclassified colitis, as focal active gastritis in the absence of ulceration
may be a CD feature (Van Assche et al 2010a, Stange et al 2008).  Formerly, only
radiographical techniques were available for examinations of the entire small bowel.  In
recent years, new radiation-free techniques for small bowel examinations have been
introduced.  Small bowel wireless capsule endoscopy (WCE) serves in making a diagnosis
and is used for assessing the severity of small bowel CD, but is contraindicated if
suspected or documented intestinal strictures exist (Leighton et al 2007).  Double-balloon
enteroscopy (DBE) is a novel technique that enables endoscopic examination of the entire
small bowel.  The scope can be inserted either by oral or anal route (Yamamoto et al
2001).
2.3.4.2 Radiological techniques
Radiological techniques are mainly used for the examination of the small bowel and
extramural complications of IBD.  The gold standard for small bowel examination has
traditionally been small bowel barium examination (SBE), with either by using an
enteroclysis or a small-bowel follow-through. As SBE is invasive and requires ionizing
radiation, it is not suitable for follow-up (Horsthuis et al 2007).  Computed tomography
(CT) and magnetic resonance imaging (MRI) are accurate methods for examining
extramural complications of IBD, although CT can not be considered suitable for repeat
use  because  of  its  associated  radiation  burden.   MRI  is  more  suitable  for  fistula  imaging
because of its high contrast resolution (Horsthuis et al 2007).  MRI enteroclysis is superior
to conventional SBE in imaging of small bowel lesions in CD (Rieber et al 2000).
However, as superficial lesions are not accurately visualized with CT or MRI enteroclysis,
WCE is preferred in examining inflammatory lesions especially in the jejunum (Gölder et
al 2006).  In the hands of an experienced operator, abdominal ultrasound can reveal small
bowel or colonic inflammation in 80-90%, though this is unspecific.  It can also be used
for detecting fistulas and abscesses (Parente et al 2003).
2.3.4.3 Laboratory findings
Initial laboratory investigations of IBD should include a full blood count, C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), creatinine, electrolytes and liver
enzymes. Microbiological testing for infectious enteritis including clostridium difficile
toxin  is  needed  for  differential  diagnosis.   Anaemia  and  thrombocytosis  are  common  in
the blood count of patients with active IBD (Stange et al 2008).  Especially in CD, CRP
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correlates with disease activity (Vermeire et al 2004)  and  it  helps  to  identify  those  UC
patients with severe exacerbation that needs colectomy (Travis et al 1996).  Low serum
protein or low serum albumin is indicative of protein loss or malabsorption (Nikolaus and
Schreiber 2007).  Faecal calprotectin can be used for monitoring disease activity, but is not
specific for IBD (Konikoff and Denson 2006, Sipponen et al 2008).
2.3.4.4 Histology
Histological examination of biopsies taken from the colon and ileum are required for the
diagnosis of IBD.   In the initial ileocolonoscopy examination, multiple mucosal biopsies
should be taken from each segment of the colon (right, transverse, left, sigmoid colon and
the  rectum)  and  the  ileum.   Histology  helps  in  distinguishing  between UC and CD,  and
between IBD and other inflammatory disorders of the gastrointestinal tract (Van Assche et
al 2010a).
Typical microscopic features of CD include focal or patchy inflammation with
granulomas, crypt architectural irregularity, increased basal cellularity (mainly
plasmacytes and lymphocytes), erosions, and mucin depletion.  In ileal biopsies, the same
features, and also irregular villous architecture can be seen.  Crypt atrophy is more
pronounced in UC.  Basal plasmacytosis, mucosal atrophy and crypt epithelial neutrophils
are also seen.  Inflammation in UC is typically continuous with a decreasing gradient of
inflammation  from  the  distal  to  the  proximal  colon.   Basal  plasmacytosis  decreases  and
can disappear during treatment (Jenkins et al 1997, Stange et al 2008, Van Assche et al
2010a).
2.3.5 Assessment of disease activity
A global measurement of IBD activity that comprises clinical, endoscopic, biochemical
and pathological features is not available (Sostegni et al 2003) but activity can be
measured by endoscopic or clinical activity scores.  The most commonly used clinical
activity score in CD studies is the Crohn’s disease activity index (CDAI).  The CDAI
comprises eight clinical variables, which are: the number of liquid stools, abdominal pain,
general well-being, extraintestinal complications, the use of antidiarrhoeal drugs,
abdominal mass, hematocrit, and body weight.  The CDAI scores range from 0 to
approximately 600.  The limit between remission and active disease is CDAI 150 and the
cut-off value between active and severe disease is 450 points (Sostegni et al 2003).
Another widely used clinical activity index for CD is the Harvey Bradshaw index, which
is based on five variables, namely: the number of liquid stools, abdominal pain, general
wellbeing, extraintestinal manifestations and abdominal mass (Harvey and Bradshaw
1980).  A score of less than five in the Harvey Bradshaw index is usually the limit for
clinical remission (Tibble et al 2000).  As patients with fistulising disease may score very
low in the CDAI and the Harvey Bradshaw indices, the Perianal Crohn’s disease Activity
Index (PDAI) was introduced.  The PDAI includes five items: discharge, pain, restriction
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of sexual activity, type of perianal disease, and degree of duration.  The PDAI is
considered at present the gold standard for evaluating the severity of perianal disease
(Irvine et al 1995, Sostegni et al 2003).
     Endoscopic activity in CD can be measured against a Crohn’s disease endoscopic index
of  severity  (CDEIS)  that  ranges  from  0  to  44  according  to  mucosal  lesions  present  and
distribution of the disease (Mary et al 1989). The scoring system is time-consuming and
requires an analogue scale transformation that makes it unsuitable for everyday clinical
practice (Sostegni et al 2003).  It also correlates poorly with clinical activity (Cellier et al
1994).  Simple endoscopic score for Crohn’s disease (SES-CD) is a simpler assessment
that is based on four endoscopic variables scored in five endoscopic segments, which
yields scores ranging from 0 to 60 (Daperno et al 2004).  For postsurgical disease activity
evaluation, the Rutgeert’s score is the gold standard (Sostegni et al 2003).
The most commonly used activity indices for UC are modifications of Truelove and
Witt’s criteria, such as the Lichtiger score and the Mayo score (Truelove and Witts 1955,
Lichtiger et al 1994).  These activity indices include some or all of the following items:
stool frequency and form, urgency/incontinence, nocturnal diarrhoea, use of anti-
diarrhoeal medications, blood per rectum, abdominal pain, well-being, extraintestinal
symptoms,  rectal  prolapse,  fever,  laboratory  tests,  physician’s  assessment,  anorexia,  and
nausea/vomiting (Turner et al 2009).  The Mayo Score is the most commonly used index
that combines both endoscopical and clinical findings.  It consists of four items with three-
point scales for the following: stool frequency, rectal bleeding, findings of flexible
sigmoideoscopy, and physician’s general assessment. Scores range from 0 to 12 points,
and patients in complete remission score 0 points (Schroeder et al 1987). Clinical
improvement is usually defined as a decrease from baseline of the score  3 points. The
Mayo Score has not been validated. (D’Haens et al 2007).  The non-invasive 9-point
Mayo score has been found to perform as well as the full Mayo score for assessing clinical
response (Lewis et al 2008).
2.3.6 Surgery
Indications for colectomy in UC are severe acute colitis that does not respond to therapy,
chronically active disease that causes steroid dependency, and dysplasia or cancer of the
colon (Andersson and Söderholm 2009).  Nowadays, restorative proctocolectomy with
ileal pouch-anal anastomosis (IPAA) is the standard care for elective surgery for UC
(Travis et al 2008).  A total abdominal colectomy with an end ileostomy and the rectal
stump left behind is a good alternative for patients requiring emergent surgery for UC.  In
such cases a restorative operation can be performed when the patient has fully recovered
(Grucela and Steinhagen 2009).  Total colectomy with ileostomy is recommended for
individuals with impaired sphincter function, advanced age, significant comorbidities or
distal rectal cancer (Cohen et al 2005).
Surgery for CD may be necessary for disease-related complications and emergencies,
such as perforation or intestinal obstruction. It may also be used for the control of
symptoms when medical therapy is not useful or has failed, such as in case of strictures,
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fistulas or neoplasia (Penner et al 2005, Kiran et al 2010).   After ileocaecal resection for
CD, 52-72% of patients develop a recurrence and 35% have had repeat resection surgery
within 10 years follow-up (Rutgeerts et al 1984, Cullen et al 2007).  Smoking is a risk
factor for recurrence (Papay et al 2010).
 The cumulative 10-year colectomy rate for UC is about 10% (Solberg et al 2009).
The 10-year cumulative surgery rate for CD is higher, 40% (Wolters et al 2006a, Solberg
et al 2007), and within a year from diagnosis, 12% of CD patients will have undergone
resection (Vind et al 2006).  More than three quarters of CD patients will require surgery
at some point of their disease (Penner et al 2005).  In northern Europe, colectomy rates for
UC and overall surgery rates for CD are higher than in southern Europe, which suggests a
more severe disease course in the north (Wolters et al 2006a, Wolters et al 2007).
Although immunosuppressants have been used more frequently during the last 25 years,
no significant decrease in the need of surgery has occurred (Cosnes et al 2005, Domènech
et al 2010).  The overall pouch function is good for most patients after IPAA surgery, and
the majority of the patients are satisfied with their pouch function (Ferrante et al 2008).
However, the functional result of the pouch is not always satisfactory.  In a Swedish
study that comprised 370 IPAA patients, median bowel frequency was six times per 24
hours and 76% of the patients had to empty the reservoir during the night. In addition,
23% of patients experienced urgency, 12% evacuation difficulties and 17% soiling during
the day (Berndtsson et al 2007).
Idiopathic inflammation of the pouch mucosa, “pouchitis”, occurs in up to 58% of
operated CU patients (Kuisma et al 2004, Ferrante et al 2008).  Patients with associating
PSC (Penna et al 1996) or ankylosing spondylitis (Kuisma et al 2004) are particularly at
risk.  Chronic pouchitis, stricturing or pouch fistulas can lead to pouch failure and the need
for permanent ileostomy in about 5% of the cases (Lepistö et al 2002, Ferrante et al 2008).
However, of 19 patients with chronic pouchitis and impaired HRQoL, over 80% would
still undergo IPAA operation again (Turina et al 2006).
2.4 Medical therapy
Medical therapy of IBD is designed in conjunction with the patient according to disease
activity, location (ileal, ileocolonic, colonic, rectal) and disease behaviour (relapse
frequency, response to previous medications, fistulas, strictures, and extraintestinal
manifestations).  Patients should be encouraged to participate in therapeutic decisions.  In
some CD patients with a mild disease, no medication can be an option.  In contrast,
therapy is usually needed for rectal bleeding and urgency occurring often even in mild
rectal inflammation for UC (Stange et al 2008, Van Assche et  al 2010a).  As smoking
cessation  is  associated  with  a  more  benign  disease  course  for  CD,  and  non-smoking
patients have higher rates of response to infliximab therapy, smoking cessation should be
recommended to all smokers with CD (Cosnes et al 2001, Parsi et al 2002).
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2.4.1 Aminosalicylates
Oral 5-aminosalicylate (5-ASA) containing compounds are the preferred first-line
maintenance  treatment  for  UC.   The  minimal  effective  dose  of  oral  5-ASA  is  around  1
g/day and higher doses up to 2.4 g/day may be more effective in patients with extensive
disease.  Sulfasalazine is equally effective to mesalazine but has more adverse effects than
mesalazine (Travis et al 2008).
Mesalazine suppositories or foam enemas (1 g/day) are the preferred initial treatments
for mild or moderately active proctitis, and have a better effect than oral mesalazine alone
(Gionchetti et al 1998).  A combination of oral and topical 5-ASA appears to provide
further benefit.  Mild to moderate, active UC should be initially treated with mesalazine at
a dose of >2 g/day, preferably in combination with topical mesalazine. However, oral
aminosalicylates alone can induce remission in a minority of patients (Travis et al 2008).
The effect of 5-ASA on the induction or maintenance of remission in active ileal or
colonic CD is limited (Hanauer and Strömberg 2004).  After curative surgery for ileal CD,
mesalazine is useful in decreasing the rate and severity of endoscopic recurrences and can
be used in low-risk patients (Brignola et al 1995).
2.4.2 Corticosteroids
Corticosteroids have been used since the 1950’s when Truelove and Witts published their
study regarding the positive effect of cortisone therapy in active UC (Truelove and Witts
1955).  Corticosteroids are used as a first-line therapy for active IBD, and over 50% of UC
patients have an associated remission (Ho et al 2006).  In comparison, 38% of CD patients
had remission for a year after corticosteroid therapy (Ho et al 2006).  No difference
between classic corticosteroids and placebo exists after 6, 12, and 24 months with
maintenance therapy for CD (Steinhart et al 2003).
     Enteric-coated budesonide has a high anti-inflammatory activity combined with low
systemic and steroid activity. Moreover, it has fewer systemic side-effects than
conventional corticosteroids because of its rapid hepatic conversion to metabolites. In
mildly active ileal or ileocaecal CD, it has been found to be beneficial.  However, for
maintenance therapy that exceeds one year, the relapse rates equal those of placebo
(Greenberg et al 1994, Greenberg et al 1996).  Budesonide is less effective than
prednisolone, and severely active or extensive ileocaecal or ileal CD should be treated
initially with systemic corticosteroids (Dignass et al 2010).
2.4.3 Immunomodulators
The immunomodulative medications, thiopurines (azathioprine and 6-mercaptopurine) and
methotrexate are recommended for steroid-dependent or steroid-refractory patients (Travis
et al 2008).  Thiopurines are also recommended for the postoperative prophylaxis of
complex CD and for the extensive small bowel CD (Dignass et al 2010).  A study reported
26
that 53% of patients that received azathioprine for steroid-dependent UC achieved clinical
and endoscopic remission after six months, whereas the rate was 21% for those that
received mesalazine (Ardizzone et al 2006).  Thiopurines are effective therapy for
inducing remission in active CD (Prefontaine et al 2010).  In those cases that need rapid
induction of remission, thiopurines alone may be insufficient, as the onset of action is
slow (Travis et al 2008, Dignass et al 2010).
Methotrexate is beneficial in inducing remission in active CD at an intramuscular dose
of 25 mg weekly, and it is also significantly more effective than placebo in maintaining
remission (Feagan et al 1995, Patel et al 2009).  For the present, data on methotrexate for
maintenance of remission in UC are few (Travis et al 2008).
2.4.4 TNF  blocking agents
Infliximab is an intravenously administered, chimeric anti-tumour necrosis factor (TNF)
monoclonal antibody with a potent anti-inflammatory effect.  It is indicated for moderate
to severe corticosteroid refractory or corticosteroid dependent IBD, or after failure of other
immunosuppressive therapy (Dignass et al 2010).   Infliximab  is  usually  given  as  an
induction regimen at 0, 2, and 6 weeks at a dose of 5 mg/kg, followed by a maintenance
regimen of 5 mg/kg every 8 weeks.  A dose of 10 mg/kg can be considered for those
patients who lose their response after initially responding (Rutgeerts et al 2004).
Infliximab is effective for inducing remission and healing endoscopic lesions in active
CD.  Up to 80% of patients clinically respond and over 30% go into remission (Targan et
al 1997). In a large multicenter study, 42% of the patients who received systematic
maintenance therapy after successful induction therapy were in remission at 1 year follow-
up (Hanauer et al 2002).  Infliximab is also effective in fistulizing CD, and closure of all
fistulas appears in up to 50% of patients after three infliximab infusions.  The median time
to relapse was 12 weeks, which shows the necessity of maintenance therapy for the
majority of patients (Present et al 1999).
     Infliximab  is  also  an  effective  rescue  therapy  for  patients  who  experienced  an  acute
severe or moderately severe attack of UC, and it decreases the rate of colectomy
significantly in a three months follow-up (Järnerot et al 2005).  However, only 24% of
patients having maintenance therapy were reported to achieve steroid-free remission at 12
months’ follow-up (Rutgeerts et al 2005).
Adalimumab, a fully human anti-TNF  monoclonal antibody, was shown to be
effective for inducing remission in TNF -naïve CD patients at a dose of 160 mg at week 0
followed by 80 mg at week 2 (Hanauer et al 2006).  Moreover, 46% of patients were
reported to be in remission after one year (Sandborn et al 2007).  Adalimumab is usually
administered subcutaneously every other week at a dose of 40 mg in maintenance therapy.
There is also some preliminary evidence that adalimumab is clinically beneficial for about




Calcineurin inhibitors are an option for a rescue therapy for steroid-refractory UC.
Because of their nephrotoxicity, they are recommended for induction therapy for only 3 to
6 months, until slower-acting immunomodulators, such as azathioprine become effective
(Travis et al 2008).
     Intravenous cyclosporine is effective for patients with severe corticosteroid-resistant
UC with a seven-day mean length of time to a response (Lichtiger et al 1994).
Calcineurin inhibitors reduce the short-term colectomy rate, but the relapse risk remains
high in the first year after treatment (Cohen et al 1999, Moskovitz et al 2006).
Tacrolimus may have an effect in the short-term clinical improvement of refractory
UC patients. More data are needed to determine the long-term efficacy and safety
(Baumgart et al 2008).   Calcineurin inhibitors are of limited value for CD (Dignass et al
2010).
2.4.6 Antibiotics
For mild to moderate flare-up of CD, ciprofloxacin has been found to have similar
efficacy  to  that  of  5-ASA  with  a  response  rate  of  40-50%  after  6  weeks  of  therapy
(Colombel et al 1999). Metronidazole can be used alone, or in combination with
ciprofloxacin.  They can be used for the therapy of pouchitis, for which both
metronidazole and ciprofloxacin have proved to be beneficial (Pardi and Sandborn 2006).
However, antibiotics can not be considered effective in inducing or maintaining remission
for UC (Travis et al 2008).
2.4.7 Nutritional therapy
Malnutrition, caused by reduced food intake, presence of active inflammation and enteric
loss of nutrients, is a common problem with active IBD, especially for CD (Hartman et al
2009).  IBD is associated with disturbances in body composition, so both bone mineral
content and lean body mass are lower than those of healthy subjects.  This is most striking
for males with CD (Jahnsen et al 2003).  Enteral nutrition, usually liquid preparations
containing aminoacids or whole protein, can be used to induce or maintain clinical
remission, and to improve nutritional status and body composition.  Nowadays parenteral
nutrition is mainly used for treatment of severe malnutrition and as a pre- or postoperative
nutritional support, as enteral nutrition is as effective with lower costs and fewer side
effects (Hartman et al 2009).   Elemental  or  polymeric  diets  are  less  effective  than
corticosteroids in the treatment of active CD (Dignass et al 2010).  No convincing data on
effects of different elimination diets for the treatment of IBD exist (Yamamoto et al 2009).
Because of the increased risk for osteoporosis, sufficient intake of calcium and vitamin
D is necessary (Ali et al 2009).  Anaemia is a common finding with IBD, and it should be
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treated by optimizing therapy of active IBD, and by administrating oral, or in some cases,
intravenous iron supplements (Gisbert and Gomollón 2008).
2.5 Comorbidity
2.5.1 Autoimmune diseases
In a recent population-based study from the US, the risk for ankylosing spondylitis was
found to be substantially higher for IBD patients than in the general population with an
odds ratio (OR) of up to 7.8.  Moreover, prevalences of atopic dermatitis, psoriasis or
multiple sclerosis were increased by approximately 1.5-fold.  No increased risk for type I
diabetes mellitus was observed (Cohen et al 2008).  The risk for demyelinating diseases
has been found to be increased in other surveys, as well (Gupta et al 2005).  The risk for
rheumatoid arthritis is also increased with IBD (OR 1.8-2.7) (Bernstein et al 2005, Cohen
et al 2008).  Clustering of many autoimmune diseases in the first-grade relatives of IBD
patients has also been observed (Hemminki et al 2010).
2.5.2 Pulmonary diseases
A broad spectrum of respiratory symptoms (such as wheeze, cough, dyspnoea and sputum
production) and lung diseases have been associated with IBD. The most commonly
reported lung diseases are bronchiectasies, acute and chronic bronchitis and asthma
(Bernstein et al 2005, Black et al 2007).  Incidences of many pulmonary diseases, such as
bronchiectasies, bronchiolitis and interstitial pulmonary disease, are increased in IBD
independently of smoking habits or medication (Mahadeva et al 2000).
2.5.3 Thromboembolic and vasculatory disease
Many predictors of atherosclerotic disease, such as levels of carotid arterial stiffness,
homocysteine, high-sensitivity CRP, and insulin resistance that support the increased risk
for early atherosclerosis are evident in IBD (Papa et al 2005, Brezenger et al 2006, Dagli
et al 2010).  On the other hand, IBD patients with coronary heart disease (CHD) have been
found to have lower Framingham risk scores (fewer risk factors) than patients with only
CHD (Sappati Biyyani et al 2009).
     A large population-based study from Manitoba, Canada reported that the risk for
ischaemic heart disease was increased in both sexes with CD and with UC, and reported
an incidence rate ratio (IRR) of 1.26 (CI 1.11-1.44).  Furthermore, an increased risk for
cerebrovascular disease was seen in CD (IRR 1.32, CI 1.05-1.66) (Bernstein et al 2008).
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In another study, increased risk for myocardial ischaemia could be confirmed only in
females aged over 40 (hazard ratio 1.6) (Ha et al 2009).  However, mortality for
cardiovascular diseases has not been found to be elevated in IBD patients (Dorn and
Sandler 2007).
 Coagulation and fibrinolysis, rate of venous thromboembolic complications, which
have been shown to be interrelated with inflammation, are also increased with IBD
(Danese et al 2007).  The most common thromboembolic complications are pulmonary
embolism and deep vein thrombosis with over a three-fold risk compared to the general
population (Miehsler et al 2004).
2.5.4 Malignancies
UC has long been known to be associated with increased risk of colorectal cancer (CRC)
and the risk increases with a longer duration and with the extent of the disease. More
recently, increased risk of CRC has been associated with CD, as well (Bernstein et al
2001b).  In a meta-analysis, the cumulative probability of CRC in UC was 2% by 10
years, 8% by 20 years and 18% by 30 years of disease duration (Eaden et al 2001).  In
IBD patients, 3% of CRC diagnoses are made coincidentally on pathological specimens
after colectomy for other reasons (Kiran et al 2010).  In a 20 years follow-up study,
dysplasia or cancer was detected in 43% of UC patients who attended surveillance
colonoscopies. The mortality of all the patients who attended the study was not increased,
however.  This was probably due to the surveillance program and frequent medical check-
ups (Lindberg et al 1996).   The risk of small bowel carcinoma in CD is increased 40-fold
(Jess et al 2006).
The risk of hepatobiliary carcinoma is also increased with both UC and CD, and most
cases are associated with PSC (Bernstein et al 2001b). A study showed that in some
patient cohorts cholangiocarcinoma can be found in 50% of PSC patients within one year
after the diagnosis (Fevery et al 2007).
A large population-based study reported an increased risk of lymphoma in male CD
patients (IRR 3.63, CI 1.53-8.62) (Bernstein et al 2001b).  Lung cancer appears to be
increased for CD compared to UC or the general population, probably due to the high
prevalence of smoking in CD (Masala et al 2004).
2.5.5 Psychiatric conditions
Psychological comorbidity, mainly anxiety and depression, are frequent findings with IBD
(Addolorato et al 1997, Miehsler et al 2008).  Both depression and anxiety are found
significantly more often for IBD than for control populations, and they are related to
frequency of disabling symptoms and also to the nutritional level (Addolorato et al 1997).
Increased levels of anxiety, depression and distress have been found in inactive IBD
patients, as well (Farrokhyar et al 2006, Graff et al 2009).  An Austrian study used a
validated questionnaire, which evaluated the need for psychological treatment, and found
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that 24% of IBD patients expressed a need for psychosomatic support. The rate was
significantly higher than for age matched and sex matched rheumatoid arthritis patients.
Inadequate social support and anxiety appeared to increase the need for psychological
intervention especially in younger age (Miehsler et al 2008).
Higher levels of depression or anxiety at baseline may be related to more frequent
relapses of IBD (Mittermaier et al 2004).  Furthermore, increasing the number of stressful
events appeared to increase risk of relapse in previously inactive UC patients after
controlling for demographic factors (Bitton et al 2003).  In another study, short-term stress
was not associated with exacerbations for UC patients, but long-term stress was a risk
factor for relapses, which emphasizes the biopsychological origin of diseases (Levenstein
et al 2000).  However, some studies found no evidence of impact of psychosocial stress on
disease exacerbations.  Instead, an increase of physical symptoms led to increased level of
psychological disturbance (North et al 1991).  In some studies, IBD patients with active
disease were more likely to use maladaptive, avoidant coping strategies than patients with
inactive disease or the general population (Graff et al 2009), but in others, no differences
in coping strategies were found between inactive and active patients or between patients
with  CD  and  UC  (Larsson et al 2008). Evidence of the effect of cognitive-behavioral
treatment for reducing psychological distress and disease-related concerns in IBD patients
exists (Mussell et al 2003).
2.6 Education level and working capacity
The level of education of young IBD patients in Scotland was similar to their peers
although 40/70 (57%) of the patients reported absences of two months or more from
school because of their disease, and many reported that their education had been adversely
affected by the disease. 6/70 (8.5%) of IBD patients were involuntarily unemployed
(Ferguson et al 1994).  A Norwegian study reported that 11.7% of the patients were
unemployed at five years follow-up after diagnosis of IBD, whereas the average
unemployment rate in the Norwegian population was 4.1%.  A rise in disability pension
rates  was  recorded  for  CD  patients  aged  30  to  50  years.   Furthermore,  CD  patients  had
twice as many sick-leave days as the general population, whereas the rate for UC was only
slightly elevated.  Unemployment was associated with significantly lower HRQoL scores
for UC patients (Bernklev et al 2006).  The ACT 1 and 2 studies examined the efficacy of
infliximab  in  therapy  of  UC,  as  well  as  the  employment  status  of  patients  and  their
HRQoL.  At week 30, among the 257 patients who were unemployed at the beginning of
the study, a greater percentage of those in remission were employed than of those not in
remission (58.8% versus 20.0%, p<0.05), and the number fully productive hours worked
was greater for those in remission (Reinisch et al 2007).
     In  a  study  comprising  both  UC  and  CD  patients  with  permanent  ileostomy,  36%
reported that before surgery their illness prevented them from pursuing a career of their
choice.  After surgery, 64% of the patients had the same job status as held preoperatively,
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and 13% worked more and 22% less than before surgery.  Moreover, 15% had lost their
jobs  after  surgery,  and  nearly  half  of  them thought  that  it  was  because  of  the  ileostomy
(McLeod et al 1986).
2.7 Health-related quality of life (HRQoL)
2.7.1 Definition of HRQoL
The WHO’s defined health in 1948 as: “a state of complete physical, mental, and social
well-being  and  not  merely  the  absence  of  disease  or  infirmity”,  which  should  be
considered more as an ideal rather than a reality. The  concept  of  “quality  of  life”
describes the general well-being of an individual or a society.  It is distinct from health,
but  health  is  one  of  the  parameters  most  strongly  associated  with  experienced  quality  of
life. Other parameters of quality of life include wealth and employment, environment,
education, recreation, leisure time, and social inclusion or exclusion (Flanagan 1978).  The
relative importance of essential issues related to the quality of life has been studied.  In an
UK study, respondents most often mentioned relationships with family or relatives (31%),
their own health (23%), the health of another person (20%), and finances/standard of
living (10%) as the most important issues related to quality of life. Those who reported
their health to be impaired, were most likely to mention their own health as the most
important issue affecting quality of life (Bowling 1995).
HRQoL indicates the overall effect of a disease on a person’s ability to enjoy life.  It is
a measure of the functional impact of a (chronic) illness and a given therapy on the daily
life of an individual, as seen from that individual’s viewpoint (Fitzpatrick 1992, Wilson
1995).
Most conceptualistic models of HRQoL include the dimensions of physical, social and
role  functioning,  in  addition  to  mental  health  and  general  perceptions  of  health  (Wilson
1995).  These dimensions impinge on each other, and they are affected by the patient’s
personality characteristics, social support, economical support, and non-medical factors,
such as political and cultural factors (Fitzpatrick 1992, Wilson 1995).
2.7.2 Applications of quality of life measurement
The need for HRQoL evaluation has arisen to meet the objective of medical therapy to
improve patients’ general well-being, which is the most important reason for HRQoL
measurement (Ebrahim 1995).  HRQoL measurement helps to identify the most
appropriate choice between different therapies with their benefits and adverse effects
(Sajid 2007).  On the population level, HRQoL measurement can be used for monitoring
population health and changes in it, for evaluating the effects of health and social policies,
and for allocating health care resources in relation to need.  On an individual level,
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HRQoL measurement serves to evaluate the effects of treatment, to describe the nature
and severity of a disease, and to assess prognosis (Ebrahim 1995).
HRQoL measurement has become an essential outcome of cost-effectiveness and cost-
utility analyses, as well.  A quality-adjusted life year (QALY) can be thought as a year of
life that is lived at an optimal state of health.  If a medical intervention adds 10 years of
life,  and  each  of  these  years  is  associated  with  a  HRQoL score  of  0.7  (of  the  maximum
being 1.0), that medical intervention will result in a gain of seven years (10 x 0.7) of
perfect health or QALYs (Muennig 2002).  Therefore, HRQoL instruments measure the
impact of a treatment on the quality of life without incorporating influence on the length
of life, whereas QALY assessment combines both quantity and quality of life into a single
value. In addition, the cost of the intervention is integrated into the cost-effectiveness
analyses (Raisch 2000).  The accepted cost-effectiveness threshold varies across different
countries depending on the availability of health-care resources and technology, as well as
on general valuations (Ebrahim 1995, Devlin and Parkin 2004).
2.7.3 Assessment of HRQoL
The  purpose  of  the  HRQoL  instruments  is  to  calculate  a  score  based  on  a  person’s
perception  of  his/her  quality  of  life.   The  HRQoL  score  is  therefore  a  valuation  of  life
lived in a particular state of health (Muennig 2002).  The primary source of information
for HRQoL measurement should be the patient him- or herself (Bjordal 2004).  HRQoL
questionnaires are administered by trained interviewers, proxies or by patients themselves
(self-administration). Surrogate respondents can be used to predict results that cannot be
obtained directly from the patient,  for example,  if  the patient is  too sick to complete the
questionnaire (Guyatt et al 1993).
2.7.4 Types and structure of HRQoL instruments
There are two main types of HRQoL instruments, generic and disease-specific.  Generic
instruments can be further divided into two groups: health profiles containing instruments
that attempt to measure separately all important aspects of HRQoL, and utility measures
comprising instruments that reflect preferences of patients for treatment process and
outcome, and yield a single score.  The latter can be used for cost-utility analyses (Guyatt
et al 1993).  Some generic instruments have features of both groups. Global HRQoL
assessment refers to a simple summary of overall HRQoL by using a visual analogue scale
(VAS), which is usually a horizontal line with one end indicating the worst health and the
other end the best health, and the respondent indicates the point that best reflects his/her
response to the question by placing a mark on the line.  A graded scale with a single
attribute can also be used.  These assessments are easy to perform, but do not identify
specific areas of dysfunction (Borgaonkar and Irvine 2000).
A questionnaire usually consists of several questions or items, which can be grouped
into domains or dimensions, which measure physical or emotional function, for example.
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Answers to questions are usually scored on a scale.  The Likert scale is a category scale by
which  respondents  specify  their  level  of  agreement  to  a  statement,  such  as:  1=  strongly
disagree, 2= disagree, 3= neither disagree nor agree, 4= agree, 5= strongly agree.  The
questions may have various number of answer options depending on the questionnaire.  In
some questionnaires, the score is calculated by summing the answers to all the individual
items.  However, some others use more complex calculations by utilizing preference
weights for each question.
2.7.5 Properties of HRQoL instruments
All useful HRQoL measurements must have the prerequisite characteristics that make
them useful for the purpose intended (Ebrahim 1995).
     First,  the  instrument  must  be  reliable.  The  concept  of  reliability  consists  of  three
aspects: test-retest repeatability, inter-observer repeatability, and internal consistency.
Internal consistency is a measure of the extent to which the items of the scale are related to
each other, i.e. the extent to which they measure consistent underlying concepts (Guyatt et
al 1993).
Another important characteristic of an instrument is validity. Validity refers to the
ability of the instrument to measure a predefined parameter.  The criterion validity refers
to  the  ability  of  an  instrument  to  correspond  to  results  of  the  criterion  standard  (i.e.  a
shorter version of an instrument versus the full-length instrument, “the gold standard”).
Face validity is the property of an instrument to appear to test the parameter intended,
whereas content validity refers to the extent to which a measure represents all facets of the
issue in question.  Construct validity is the agreement between HRQoL scale and
predefined expectations about how it should behave in different situations, for example,
the ability to show similarity among like groups (Guyatt et al 1993, Irvine et al 1994).
Responsiveness, or sensitivity to change, is the instrument’s ability to detect change in
HRQoL.  The terms “ceiling effect” and “floor effect” are linked with responsiveness.  If
the ceiling effect of an instrument is high, many patients gain the best score, and for these
individuals, the instrument is not capable of detecting any further improvement in
HRQoL.  Conversely, the floor effect prevents the detection of HRQoL impairment in
those subjects with the worst possible scores (Guyatt et al 1993, Ebrahim 1995).
A  good  HRQoL  instrument  is  also  feasible  for  the  researcher,  acceptable  for  the
patient, interpretable, and useful in providing tools for clinical and political decision
making (Sajid et al 2007).  An adequate validation of the instrument is important prior to
its application in clinical practice or research to minimize the risk of missing important
observations or focusing on inconsequential problems (Irvine 1996).  After these criteria
have been taken into account, there are no uniformly ‘worst’ or ‘best’ performing
instruments.  Consequently, the instrument selection should be made by using the
characteristics that are considered most relevant to the study (Coons et al 2000).
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2.7.6 Generic HRQoL instruments
Generic instruments are often preference-based and designed to provide a summary of
HRQoL. The questionnaires have been developed by obtaining importance weights of
each  dimension  of  the  questionnaire,  and  also  by  obtaining  the  values  assigned  to  a
particular state of health from a general population sample (Muennig 2002).  Their aim is
to create a standardized health state descriptive system by choosing the correct dimensions
in which health is to be measured and by dividing each dimension into discrete levels that
correspond to different health states (Sintonen 1994).  Generic instruments can be used for
comparing health status among patients with different health states, conditions and
diseases.  However, as developed for general populations, these instruments do not focus
specifically on the impact of a particular condition on HRQoL, and they may be less
capable of detecting small but clinically important changes over time or changes related to
treatment of a specific disease (Cramer et al 2002).  Their most important function is to
enable comparisons between populations with different diseases, and also comparisons
with the general population.  Generic instruments are suitable for calculating QALYs for
cost-effectiveness analyses of different therapies (Raisch 2000).  Properties of the most
important standardized generic HRQoL instruments used in IBD are discussed below.
2.7.6.1 Medical Outcomes Study Short-Form
The Medical Outcomes Study Short-Form (SF-36) was designed to study health status in
the Medical Outcomes Study.  It is suitable to be used in clinical practice and for research,
health policy evaluations and general population surveys, and it has been widely used.  It
has  36  questions,  so  is  relatively  fast  and  easy  to  use,  and  can  be  self-administered  or
interviewer-administered (Ware and Sherbourne 1992, Brazier et al 1992).  In a study by
Essink-Bot et al, SF-36 had superior validity to that of the EuroQoL and the Nottingham
Health Profile (Coons et al 2000).  Abbreviated versions (SF-20 and SF-12) of SF-36 have
been developed, but their reliability and validity are slightly lower than those of the SF-36
questionnaire (Stewart et al 1988).
2.7.6.2  EuroQoL
The EuroQoL (EQ-5D) comprises five dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression) with three answer options, in addition to a VAS
that describes the current general health state at a scale from 0 to 100.  EQ-5D was
developed with the intent of constructing a simple, self-administered instrument that was
particularly useful when used alongside with other measures of health status. It can be
used for clinical studies, and for population surveys.  EQ-5D provides a simple descriptive
profile, and a single index value that describes health status.  In total 243 health states can
be differentiated according to answers to the five items of the questionnaire and the VAS
scale (www.euroqol.org).  EQ-5D has a good reliability but it has a high ceiling effect, as
with many other generic tools (Coons et al 2000).
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2.7.6.3 Sickness Impact Profile
The Sickness Impact Profile (SIP) is one of the first validated and extensively used health
state measures. It is behaviourally based and serves both as an evaluative and as a
discriminative measure (Gilson et al 1975).  SIP comprises 136 items in 12 categories.
The minimum score of 0% indicates absence of dysfunction, and 100% maximal
dysfunction.  High test-retest reliabilities have been reported for SIP.  However, its
administration is time-consuming (20 to 30 minutes when interviewer-administered).
Moreover,  the  SIP  may  fail  to  detect  small,  but  existing  differences  in  HRQoL,  or  to
detect small changes in health after treatment in those patients with mild disease because
of its high ceiling effect (Yacavone et al 2001).
2.7.6.4 Nottingham Health Profile
The  Nottingham  Health  Profile  (NHP)  was  developed  in  the  UK  for  being  used  in
epidemiological studies.  NHP assesses subjective health by using 38 statements in 6
sections requiring “yes” or “no” for an answer. The score is calculated using weighted
values, which yield scores ranging from 0 (no problems) to 100 (maximal problems) for
each section.  NHP has a high degree of relevance and acceptability to patients and it  is
simple to complete and score (Yacavone et al 2001).  In reliability testing it has shown
good test-retest correlations (Coons et al 2000).  Its main disadvantage is a relatively high
floor effect which limits its usefulness in the general population (Coons et al 2000).  The
ceiling effect is similar to that of SIP (Yacavone et al 2001), and NHP is less sensitive to
minor levels of discomfort than SF-36 (Brazier et al 1992, Ebrahim 1995).
2.7.6.5 Psychological General Well-Being
The Psychological General Well-Being (PGWB) is a 22-item questionnaire that measures
subjective feelings of well-being and distress.  Responses are graded on a six-point Likert
scale with higher values indicating better well-being. Six dimensional scores (anxiety,
depression, general health, positive well-being, self-control, and vitality), comprising three
to five items, are calculated.  The total score is the sum of the domain scores with a
maximum of 110 points.  A shorter, 6-item version of PGWB has also been developed, but
hitherto it has not been fully validated (Grossi et al 2006).  Reliability testing has shown
tendency of initially low scores to rise and initially high scores to fall in the event of re-
testing, which indicates the need for caution in interpreting results in longitudinal studies
(Yacavone et al 2001).
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2.7.6.6 15D
15D is a 15-dimensional, comprehensive instrument that yields both a profile and a single
index score measure.  15D is designed to be self-administered, though interviewer or
proxy administration can also be used.  15D includes the following dimensions: breathing,
mental function, speech (communication), vision, mobility, usual activities, vitality,
hearing, eating, elimination, sleeping, distress, discomfort and symptoms, sexual activity,
and  depression.   Each  dimension  is  rated  against  a  five-point  scale  and  the  score  is
calculated by utilizing preference weights obtained from the general population. The
maximum score is 1 (no problems on any dimension), and minimum 0 (deceased).   15D
has been used in the Finnish National Health Survey 1995/96 and the Health 2000 Survey,
thus it provides a large general population sample for comparison studies (Sintonen 2001).
With regards to the ceiling and floor effects, 15D is superior to NHP and EQ-5D and
equivalent to SF-20 (Sintonen 1994).  Responsiveness to change has been found to be
roughly comparable between 15D, NHP and SF-20 (Sintonen 2001).  Completion rates of
15D questionnaires have generally been 96-100%, and a small number of missing answers
can  be  fairly  accurately  predicted  by  regression  models  with  the  responses  on  the  other
dimensions, age, and gender as explanatory variables.  A change of 0.03 in 15D score
can be sensed by an individual (Sintonen 1994).  15D has been used in several conditions,
drug evaluations, rehabilitation and treatment studies (www.15d-instrument.net/15d). The
mean 15D score was 0.91 for the general population of the Health 2000 Survey.
Impairment of 15D scores occurs with increasing age (Saarni et al 2006). Two versions of
15D exist for studying children and adolescents; 17D for children aged 8-11 years and
16D for adolescents aged 12-15 years (Apajasalo et al 1996a, Apajasalo et al 1996b).  The
most important studies that have used 15D are shown in Tables 1 and 2.
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Purpose of study 15D score
Stavem 1998 Epilepsy 57 Comparison of different
HRQoL tools
0.89
Stavem 1999 Chronic obstructive
pulmonary disease





Diabetes mellitus 539 Measurement of HRQoL




Impairment of HRQoL with




Parkinson’s disease 260 Assessment of feasibility
of 15D in Parkinson’s
disease
0.77 (matched controls 0.86)
Dahlberg et
al 2005
Spinal cord lesion 117 Evaluation of HRQoL  0.78 (matched controls 0.95)
Yildirim
2006







Various diseases 6166 Impact of chronic





Sarcoidosis 81 Comparison of patients




































0.94 (no nocturia)/0.83 (over
two voids per night)
Mattila et al
2010
Alexithymia 5090 Assessment of HRQoL
in alexithymia




Type I diabetes 1023 Impact of diabetes and
its complications on
HRQoL
0.90 (all), impairment of
scores if diabetic
complications present
HRQoL = health-related quality of life
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2.7.7 Disease-specific HRQoL instruments
Specific instruments focus on aspects of health status that are specific to the area of
interest, such as a certain disease, condition, function or problem, or a population of
patients (Guyatt et al 1993).  Disease-specific instruments are usually more responsive to
changes in evaluation of HRQoL in a specific condition (Irvine et al 1994).  Clinical trials
that evaluate specific therapeutic interventions most often utilize disease-specific HRQoL
tools (Yacavone et al 2001).  Disease-specific HRQoL tools have been developed for
numerous diseases and conditions. Several disease-specific tools exist for evaluating
HRQoL in IBD, the most important of which are presented below.
2.7.7.1 Inflammatory Bowel Disease Questionnaire
The most commonly used HRQoL instrument in IBD, translated into over 40 languages, is
the Inflammatory Bowel Disease Questionnaire (IBDQ) (ip.mcmaster.ca/questionnaires/
questionnaires).
The questionnaire consists of 32 questions rated most important to the HRQoL by IBD
patients and their physicians. The questionnaire has four domains: gastrointestinal
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symptoms, systemic symptoms, emotional function and social function, with each domain
comprising five to 12 items.  Responses range from 1 (worst) to 7 (best).  The total score
ranges from 32 to 224, and is calculated by summing all the answers to the 32 questions.
Mean  scores  per  item  for  each  domain  (range  1  to  7)  can  also  be  calculated.   The
questionnaire has been validated and it is sensitive to change in IBD patients (Guyatt et al
1989).  However, systemic function (such as fatigue, sleep, and energy level) is more
responsive to change than emotional or social scores.  In remission, scores are generally
170 points or more, and a mean decrease in relapse is about 32 points (Irvine et al 1994,
Cregor et al 1997).
     Alternative versions of the IBDQ have been developed.  A short-form IBDQ (SIBDQ)
consists of 10 questions and has been developed for clinical use.  It is useful in both UC
and CD (Han et al 2000).  A version designed for stoma patients is also available.  The
most important surveys utilizing IBDQ are presented in Tables 3 and 4.
2.7.7.2 Rating Form of IBD Patient Concerns
The  Rating  Form  of  IBD  Patient  Concerns  (RFIPC)  was  developed  to  evaluate  disease-
related worries and concerns of IBD patients.  The questionnaire is self-administered and
has 21 items.  Items are in the form “Because of your condition, how concerned are you
with…?”  Patients rate concerns from 0 to 100 on a VAS, and the total score is the mean
of all answers (Drossman et al 1989).  This instrument is well suited  to guiding patient
education and counselling because of its focus on patient concerns (Yacavone et al  2001)
but it has also been used in HRQoL studies (Stjernman et al 2010).
2.7.7.3 Cleveland Clinic IBD Scale
The Cleveland Clinic IBD Scale was developed for use as a routine management tool for
ambulatory IBD patients. It has 47 items, of which 45 are scaled and two require
descriptive answers.  The questionnaire comprises four categories: functional/economic,
social/recreational, affect/life in general, and medical/symptoms.  The questionnaire has
not yet been fully validated (Yacavone et al 2001).
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Table 3. Overview of earlier studies with Inflammatory Bowel Disease Questionnaire
(IBDQ)
Author and year Number of
patients
Disease Main result Study purpose
Hjortswang et al
2001






Disease activity affected HRQoL Study  the influence of IBD
on different dimensions of
HRQoL
Nordin et al 2001 492 CD 161,
UC 331
Anxiety and depression impair
HRQoL





CD: mean per item 6.1
(remission/4.2 (active), UC: 6.3
(remission)/4.1 (active)
Impact of health status and
socio-demographic factors on
HRQoL
Rubin et al 2004 409 CD 163,
UC 239
IC 7
Lower HRQoL scores for
women,  in CD and for those
under specialist care






Mean per item  6.1 (remission)/
4.5 (active)






CD: 157 (sick leave)/187 (no sick
leave), 173 ( )/186 ( ); UC:174
(sick leave)/192 (no sick leave),
183 ( )/191 ( )
Impact of demographic




448 CD 193 (remission), 161 (active) Evaluation of validity of















Gibson et al 2007 143 CD 180.6 (CDAI <150), 115.4
(CDAI 220)
Impact of disease severity on
HRQoL and health-care
resource use
Vidal et al 2008 147 CD 76,
UC 71
Hospital Anxiety and Depression
Score was negatively correlated
with IBDQ scores




331 UC mean per item 5.9 (disease
duration <5 years), 6.0 ( 10years)










CD = Crohn’s disease; HRQoL = health-related quality of life; IBD = inflammatory
bowel disease; IPAA = ileal pouch-anal anastomosis; UC = ulcerative colitis
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Table 4. Overview of earlier treatment or intervention studies with Inflammatory Bowel
Disease Questionnaire (IBDQ)

































728 UC 54 weeks Significant improvement
in all IBDQ subscores













UC 30 weeks 130/195 Impact of remission




339 CD 60 weeks Significant improvement









Loftus et al 2008 499 CD 56 weeks Significant improvement















Ng et al 2009 26 CD 12 months 137/176 TNF -inhibitors in
fistulizing CD
Bastida et al 2010 92 CD 68,
UC 24
12 months 4.98/6.10 (mean score
per item)
Thiopurines
CD = Crohn’s disease; HRQoL = health-related quality of life; UC = ulcerative colitis
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2.7.8 Worries and concerns of IBD patients
The most intense concerns of IBD patients in a US study were the uncertainty of the
disease course, the effects of medication, the impact of the disease on energy level, the
risk of having surgery or an ostomy bag, being a burden on others, loss of bowel control,
and the risk of developing cancer.  In CD, concerns about energy level, being a burden on
others, not achieving full potential, having pain, and incurring financial costs were more
pronounced than in UC, whereas concerns of developing cancer or other complications of
the disease were more often seen in UC.  Females were generally more concerned about
issues associated with the body image, and younger individuals were more worried about
impact of the disease on sexual intimacy (Drossman et al 1991).  Females, patients with
active disease, and overweight patients have higher levels of worries and concerns
(Stjernman et al 2010).
The most intense concerns of patients with ileostomy were issues related to intimacy,
access to medical care, energy level, loss of sexual drive, loss of ability to perform
sexually, producing unpleasant odours, being a burden on others, attractiveness, and
feelings about the body (Carlsson et al 2003).
2.7.9 Predictors of HRQoL in IBD
2.7.9.1 Disease-related factors
Disease severity and activity are the most important determinants of HRQoL as measured
by the IBDQ (Irvine et al 1994, Casellas et al 2002, Hjortswang et al 2003) and the SF-36
(Hjortswang et al 2003).  The need for hospitalization reflects the disease activity and is
associated with lower HRQoL scores (Blondel-Kucharski et al 2001, Casellas et al 2002).
In most surveys, there were no significant differences in HRQoL between UC and CD
patients after severity of disease had been taken into account (Casellas et al 2002, Guthrie
et al 2002).  A US study found that CD patients with colonic disease had better disease-
specific  (IBDQ) and  generic  (SF-36)  HRQoL scores  than  had  patients  with  small  bowel
disease or those with fistulizing or stricturing disease (Lix et al 2008).  This finding was
not seen in an earlier European study, in which disease activity determined the IBDQ
scores, not the Vienna Classification (Casellas et al 2005b).  The knowledge about impact
of age on HRQoL is controversial,  but longer disease duration may predict better HRQoL
scores at least for some disease groups (Casellas et al 2002, Canavan et al 2006, Zahn et
al 2006).   Little  is  known  about  HRQoL  in  patients  with  both  IBD  and  PSC.  A  recent
study comprising 26 IBD-PSC patients and IBD patients without PSC, who were matched
for gender, age, disease type and disease duration, found that both groups had similar
SIBDQ scores (Ananthakrishnan et al 2010).
Patients  who  have  undergone  surgery  for  CD  report  worse  HRQoL,  as  evaluated  by
IBDQ, than reported by non-surgical CD patients (Canavan et al 2006).  After surgery for
CD, HRQoL was improved 3 and 6 months postoperatively.  After 12 months, due to
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disease recurrencies, there was no significant difference for RFIPC score compared to
preoperative values. However, for those patients still in remission, the postoperative
HRQoL was significantly better than that preoperatively (Tillinger et al 1999).
The  post-surgical  situation  of  UC  patients  is  different.   After  ileostomy  and  IPAA
surgery, the function of the stoma or pouch is the most important determinant for HRQoL
(McLeod et al 1986, Lepistö et al 2002).  The impact of stoma on body image and self-
esteem of adolescents is probably more pronounced (Nicholas et al 2008). In some
studies,  patients  with  stoma  reported  better  quality  of  life  than  did  those  with  an  IPAA
(Nordin et al 2002).
2.7.9.2 Patient-related factors
Psychiatric disorders (anxiety, depression, neuroticism and alexithymia) are important and
independent predictors of poor quality of life in many surveys, and they affect the domain
of social function most strongly (Guthrie et al 2002 Moreno-Jiménez et al 2007).  Patients
with  psychological  disorders  also  have  significantly  worse  scores  for  domains  that
measure physical function, pain, and health perception in SF-36 (Guthrie et al 2002).  In a
study that controlled patients for disease activity, psychological factors were strongly
associated with perceived health in IBD (Graff et al 2009). The negative impact of
psychiatric disorders on perceived quality of life and symptom burden has been noted in
other chronic diseases, as well (Katon and Ciechanowski 2002, Scott et al 2007).
Males are associated with better HRQoL scores in most surveys (Casellas et al 2002,
Hjortswang et al 2003, Bernklev et al 2004), but not all (Han et  al 2005). Concurrent
smoking has a negative impact on HRQoL especially in CD (Blondel-Kucharski et al
2001, Casellas et al 2002, Bernklev et al 2004).  However, a Canadian study found that
smoking was related to a better quality of life for inactive IBD as measured by SIBDQ and
EQ-5D (Farrokhyar et al 2006). A higher level of education was associated with better
IBDQ scores in a Spanish study comprising 354 IBD patients, which probably was related
to socioeconomical differences between the educational groups (Casellas et al 2002).  In a
Swedish study, the educational level did not affect generic or disease-specific HRQoL, nor
did civil status, disease duration or disease extent (Hjortswang et al 2003).  Even if disease
duration does not have a significant impact on HRQoL, factors that affect HRQoL may
change along with disease duration.  In UC patients with disease duration of over 10 years,
complications due to corticosteroids, such as osteoporosis, were thought to be the most
striking factors that impaired HRQoL in a study performed in Japan (Kuriyama et al
2008).  However, the medication of the study patients differed somewhat from preferred
therapy in Finland.
A Canadian study found that patients with inactive IBD have significantly more
functional gastrointestinal disorders than the general population as determined by Rome II
criteria.  These symptoms increase anxiety, and impair both generic (as measured by EQ-
5D) and disease-specific (SIBDQ) HRQoL (Farrokhyar et al 2006).  There is evidence that
co-existing diseases impair HRQoL in IBD (Hjortswang et al 2003).  Nevertheless, IBD
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severity is the most important predictor of HRQoL for those with other chronic conditions
in addition to IBD (Pizzi et al 2006).
Short-term  benefits  of  some  aspects  of  HRQoL  and  general  well-being  have  been
achieved with a comprehensive lifestyle modification programme which included stress
reduction, stress management, and dietary and exercise guidance for 10 weeks.  Three
months after the intervention, patients of the intervention group showed significant
improvement in the SF-36 scale compared with the usual-care control group.  However,
12 months after the intervention, no difference was observed between the groups
(Langhorst et al 2007).  A group-based education programme for particularly anxious IBD
patients did not improve their anxiety levels or HRQoL, although patients reported
satisfaction with the programme and found information given on disease-related items
useful (Larsson et al 2003).  In another study, the provision of disease-related information
in the form of educational booklets worsened short-term HRQoL as measured by IBDQ
(Borgaonkar et al 2002).  The same was seen in a Swedish study, in which a group-based
intervention programme comprising educational lectures and therapy sessions was given.
Those with short disease duration ( 3 years) benefited from the programme, whereas the
HRQoL of patients with longer disease duration worsened during the follow-up
(Oxelmark et al 2007).
2.7.10 Impact of individual IBD symptoms on HRQoL
During the development of the IBDQ, 77 ambulatory patients were asked about their
problems related to IBD.  The most disturbing symptoms were frequent or loose stools,
abdominal pain and rectal bleeding.  Patients experienced constitutional symptoms, such
as fatigue, sleeping difficulties, and problems in maintaining weight as being more
disturbing than emotional problems (irritability, anger and depression) or social problems
(such as the need to cancel social events, or being unable to attend leisure-time activities,
work or school).  Even so, social and emotional problems were still seen as noteworthy.
UC patients reported less fatigue and better well-being (p<0.05) than did the CD patients
(Mitchell et al 1988). Non-inflammatory joint pain, which is common in IBD,
significantly impairs IBDQ and SF-36 scores (Bernklev et al 2004, Palm et al 2005).
2.7.11 Impact of therapy on HRQoL
A Spanish survey reported that HRQoL (measured by IBDQ, EQ-5D, and PGWB) was
similar for CD patients in remission, irrespective of whether remission had been achieved
medically or surgically.  The survey also included stoma patients (Casellas et al 2000).  A
large European survey found that two-thirds of patients (both UC and CD) rated their
quality of life after surgery as greatly improved.  However, after surgery, 65% of patients
reported a recurrence of symptoms, and 58% reported postoperative complications (Ghosh
and Mitchell 2007).  In UC patients who had undergone colectomy and IPAA surgery,
HRQoL highly depended on pouch function, and the patients with poor pouch function or
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pouch failure had significantly lower SF-36 scores than did those with good pouch
function (Lepistö et al 2002, Berndtsson et al 2007).   In  comparison,  there  were  no
significant differences in HRQoL scores (SF-36 and IBDQ) for UC patients with IPAA or
permanent ileostomy after surgery, but those with restorative proctocolectomy appeared to
have a better perception on body image (Camilleri-Brennan et al 2003).
     HRQoL evaluations of most drugs used for IBD are available. Mesalazine has been
shown to improve HRQoL significantly in mildly and moderately active UC (Irvine et al
2008).  The use of immunomodulators is associated with a better HRQoL, whereas the use
of corticosteroids has a negative impact on HRQoL of CD patients (Blondel-Kucharski et
al 2001).  Improved HRQoL, as measured by VAS and a questionnaire designed for
evaluation of outcomes after surgery (Öresland et al 1989), was observed in patients with
severe UC treated successfully with intravenous cyclosporine, compared to their peers
who were treated surgically (Cohen et al 1999).
Infliximab has been shown to have a beneficial impact on HRQoL, as measured by
IBDQ, and the increase is in parallel with improvements of CDAI (in CD) and Mayo (in
UC) scores (Hanauer et al 2002, Reinisch et al 2007).  With active or fistulizing CD, a
rapid  improvement  in  the  IBDQ  score  was  already  evident  after  a  single  infusion  of
infliximab (van Balkom et al 2002).
2.7.12 Comparison of HRQoL with the general population and with other
disease groups
Examined with a general HRQoL tool (SF-36) and a VAS, patients with colonic CD in
remission did not differ from the general population.  In contrast, patients with active
disease scored lower for all the eight domains of SF-36, and those patients who had
undergone surgery had lower scores for those domains that measured general health and
physical role (Andersson et al 2003).  A Swedish study found that inactive UC patients
scored even better for the SF-36 dimensions of “physical function” and “bodily pain” than
did the general population (Hjortswang et al 2003).  UC patients with a well-functioning
IPAA had similar SF-36 scores to those of the general population (Berndtsson et al 2007),
although impaired scores for the domain that measures energy levels have also been
reported (Lepistö et al 2002).
Psychological distress and impairment of HRQoL as measured by SF-36 were similar
in irritable bowel syndrome (IBS) and IBD in a referral center setting (Pace et al 2003).
The 15D has earlier been used for IBD patients in a population-based survey that
measured the impact of various chronic conditions on 15D and EQ-5D scores in a sample
of citizens over 30 years of age.  The respondents were matched for age, sex, income,
education, marital status and other chronic conditions.  The mean 15D score of IBD
patients was 0.868, compared to the mean of all respondents of 0.910.  Lower scores inter
alia were determined for diabetes (0.833), urinary incontinence (0.835), rheumatoid
arthritis (0.831), Parkinson’s disease (0.748) and macular degeneration (0.798).  Patients
with psoriasis (0.888), migraine (0.903), a loss of hearing (0.872) or disturbing allergy
(0.894) had better scores than IBD patients (Saarni et al 2006).
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3 Aims of the study
The aims of the present study were to find answers to the following questions:
1. Do Finnish IBD patients have symptoms as frequently as other European
patients, and are the arrangements of their therapy different from those of
other patients in Europe? (Study I)
2. Which demographic and therapy-associated factors influence HRQoL as
measured by the disease-specific IBDQ instrument?  (Study II)
3. Is the generic 15D instrument useful for the evaluation of HRQoL in IBD,
and  do  IBD  patients  have  lower  15D  scores  than  those  of  the  general
population sample? (Study III)
4. Do  IBD  patients  have  more  comorbidities  than  those  of  the  general
population, and do comorbidities impair HRQoL? (Study IV)
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4 Patients and methods
4.1 Patients and data collection
The study was performed in cooperation with a patient organization, the Crohn’s and
Colitis Association of Finland.  Most of the study patients were recruited from the patient
organization member register, but an additional sample of individuals who had received
special reimbursement for IBD medication, as recorded in the register of Social Insurance
Institution of Finland, was recruited.  The study was performed as a postal survey, by
which the study questionnaire was first mailed to 3852 adult (over 18 years of age)
members of the patient organization in September 2006.  The study questionnaire was
posted to an additional 1490 adult patients selected by random sampling from the national
register in February 2008.  The national register included about 30 000 individuals who
were eligible for reimbursement for IBD medication.  The two study populations included
an overlap of the same individuals (total of 82 respondents), and for those, the latter
response was included in the analysis.  No reminders were sent.
4.2 Questionnaires
The study questionnaire comprised the 32-item, disease-specific IBDQ and the 15-item,
generic 15D questionnaires.  These were complemented by the European Federation of
Crohn’s and Colitis Associations’ (EFCCA) questionnaire with 31 questions about the
following:  the  diagnosis  and  history  of  the  disease,  current  and  previous  therapies,  IBD
symptoms and their frequency, and the impact of the given therapy and symptoms on the
experienced HRQoL.  The study questionnaire also included a section that inquired about
the utilization of health care services (not in the scope of this thesis).  The IBDQ was used
under licence from McMaster University, Hamilton, Canada, and the EFCCA gave
permission to use their questionnaire. Small modifications were made to the EFCCA
questionnaire (such as including additional questions about the education level of the
respondents).
The IBDQ and EFCCA questionnaires were translated into Finnish and Swedish by
official translators of the Helsinki University Language Services. A back-translation to
English was performed to confirm the linguistic accuracy of the translation. The 15D was
originally available both in Finnish and in Swedish. The questionnaire was then tested on
a group of 60 IBD patients who were members of the Crohn and Colitis Association and
all the questions were easily understood.
Some patients did not answer all the questions in the questionnaire.  In such cases, the
mean scores of IBDQ were calculated from the other items of the domain.  If two or more
questions per domain were unanswered, or if the total number of unanswered items
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exceeded four, the patient was omitted from analyses, as the results and scores would not
have been reliable.  If the subject had left one to three questions of the 15D unanswered,
the missing data were replaced by predictions from linear regression analysis, based on the
other dimensions and using age and gender as the independent variables (www.15d-
instrument.net). For the EFCCA questionnaire, percentages were calculated of those
patients who had given an answer to the relevant question.
The Finnish versions of the 15D and EFCCA questionnaires are presented in Appendix
A.  Per the terms of the license agreement, the IBDQ questionnaire can not be published.
4.3 Control groups
In study I, the differences in the diagnosis of IBD, current and previous therapies,
frequency of IBD symptoms, the impact of symptoms and given therapies between the
Finnish and the European patients were compared.  The European control group
comprised the 5576 IBD patients who had participated in a survey conducted by EFCCA
with seven of its national organizations. The participating countries were Denmark, Italy,
The Netherlands, Portugal, Spain, Switzerland, and the United Kingdom (Ghosh and
Mitchell 2007).
The examination of the generic 15D scores of IBD patients in study III used a general
population sample obtained from the national Health 2000 Survey (for subjects 30 years
of age) (Aromaa et al 2004) and from the Finnish National Health Survey 1995/96 (for
subjects 18-29 years of age).  These population samples were matched for age and sex,
and served as a control group.
In  study  IV,  two  control  subjects  for  each  participant  that  were  matched  for  age,
gender and hospital district were chosen from the Social Insurance Institution register.
The aim of study IV was to compare patients with IBD with the general  population, and
the reference group included patients with IBD in proportion to their prevalence in that
particular population (0.7%).  No HRQoL data were available for the control group.
4.4 Statistical methods
Statistical analyses were performed using SPSS for Windows versions 14.0-16.0 statistical
software (SPSS Inc, Chicago, Ill., USA).  In study I, Confidence Interval Analysis version
2.1.2 (CIA, Statistics with confidence; BMJ Publishing Group Ltd., London, UK) software
was utilized.
The results are presented as percentages, means with standard deviations (SD), or
medians.  In study I, 95% confidence intervals (CI) were used. The percentages are
reported as integral numbers when they exceed 10, and to one decimal place for
percentages  less  than  10.   In  studies  I  and  IV,  comparisons  of  continuous  variables
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between the groups were performed by using analysis of variance (ANOVA).  Moreover,
ANOVA was used in study II to examine how differences in the frequency of symptoms,
the level of satisfaction with current treatment, and the arrangement of therapy affected the
IBDQ  scores.   In  studies  II  and  III,  linear  regression  analysis  served  to  estimate  how
individual demographic factors, symptoms and medications affected HRQoL scores.
Linear regression was also used for studying the patient characteristics and risk factors for
CHD in study IV.
In study III, the 15D scores were not normally distributed, thus differences in
continuous variables were analysed by the Kruskal-Wallis test when more than two groups
were present, or by the Mann Whitney U–test to examine differences between two groups.
Furthermore, in study III, correlations between 15D and IBDQ scores were tested by using
Pearson’s correlation coefficient whereas differences in the 15D scores between study
patients and the reference population were analysed by the independent samples t-test.
In study IV, the Cox regression model was used for examining the differences in the
occurrences of chronic diseases between IBD patients and their controls.  The analysis was
performed using a conditional logistic regression model that was technically implemented
by using the Cox regression model.  The matched case-control group variable was handled
as a stratum, and the follow-up time within each matched case-control subject was set to 1
so that that the cases and controls were at risk at the same time.  Further, partial
correlation with matching for age was used for estimating the impact of various chronic
diseases on HRQoL scores.  For categorical variables, tests were performed with the chi-
square test in all studies.
Many patients reported taking several different medications. Therefore, dummy
variables were used for investigating the impact of separate therapies on IBDQ scores in
study II.  The dummy variables comprised subjects with no medical treatment, subjects
with only 5-ASA medication, subjects with immunosuppressive therapy but no biological
medication or corticosteroids, subjects with biological treatment but no corticosteroids and
subjects who were having corticosteroid treatment (with any other treatment) at  the time
of the survey.  In study II, the impacts of each demographic factor and given therapy on
the IBDQ score were examined by using a sequential ANOVA approach, in which the
symptoms were first  accounted for in the model.   Thereafter,  the effect  of each factor in
turn was evaluated based on its respective residual variability in the IBDQ score.
The study population was divided into four subgroups according to the following
diagnoses: UC, CD, proctitis and indeterminate or unspecified colitis (IC).  As the last two
subgroups were considerably smaller than the first two, statistics were in some cases
calculated  only  for  the  UC  and  CD  groups.   In  study  IV,  statistical  analyses  were
performed only for UC and CD groups, and patients with proctitis were included in the
UC group.
A p-value of less than 0.05 was considered statistically significant.
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4.5 Ethical considerations
The study protocol was approved by the Ethics Committee of the Helsinki and Uusimaa
Hospital District (registration number 94/E5/06). All participants gave their written
informed  consent  for  the  HRQoL  study  and  for  the  access  and  acquisition  of  their  data
from the Social Insurance Institution register.  Non-respondents and control patients
selected from earlier population-based HRQoL studies or from the Social Insurance
Institution register could not be identified.
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Figure 2. Flow chart of the patients in studies I-IV
Questionnaires mailed to patient
association members,
n=3852















Valid for study I,
n=2424
IBDQ filled in inadequately,
n=38













Valid for study III,
n=2870
15D filled in inadequately,
n=5
Valid for study IV,
n=2831




5.1 Recruited patients (I, II, III, IV)
Of the total of 5342 questionnaires mailed, 3071 (57%) were returned.  Of those
questionnaires sent to patient association members, 64% were returned, whereas the
percentage was 42% for those mailed to patients who were selected from the Social
Insurance  Institution  register.   Of  all  the  respondents,  two  were  under  18  years,  16
reported or were suspected of not having IBD, and 24 had not signed the informed
consent. An additional 116 subjects had omitted their social identity numbers, which made
their reimbursement data unobtainable from the Social Insurance Institution, or had failed
to complete either of the HRQoL questionnaires adequately for the accurate calculation of
the HRQoL scores.  A total of 82 patients had responded twice. For each study, all the
suitable patients were included.  Figure 2 shows the flow chart of the study population.
5.2 Demographic characteristics of the patients and comparison
with the European study (I, III)
The results are given for the patient association cohort, as the control population in the
European EFCCA study also comprised members of IBD patient associations.
Differences between patient association members and patients recruited from the Social
Insurance Institution register are given in Table 5.
Of the respondents with valid responses, the majority were female. The gender
difference was mostly due to the female predominance among the members of Crohn and
Colitis Association, for which about two-thirds are female.  A predominance of females,
(57%) was also observed in the European EFCCA study (Ghosh and Mitchell 2008).  In
the current study, the majority (53%) were diagnosed with UC, 37% with CD and the rest
with proctitis or unspecified colitis.  The distribution of diseases was somewhat different
in the European study with 57% of patients having CD.  In the European study, patients
were divided into groups of CD and UC, and the smaller group of those having IC was
excluded from the analyses.  Demographic characteristics of the study population are
shown in Table 5.
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Table 5. Demographic characteristics of patients and differences between samples (studies
I & III)
















   Mean 43.3* 43.7* 43.0* 49.8* 47.9* 49.6*
   Median 42.2 41.9 41.6 48.8 46.9 48.7
   Range 18-85 18-85 18-82 18-89 23-89 20-89
Gender
   Female 67.0%* 67.1%* 65.4%* 51.5%* 60.4%* 52.8%*
   Male 33.0% 32.9% 34.6% 48.5% 39.6% 47.2%
Duration of IBD (years)
   Mean 9.5* 10.2* 9.5* 12.9* 11.9* 13.9*
   Median 8.0 8.0 7.0 10.0 11.0 10.0
   Range 0-50 0-40 0-50 0-50 0-40 0-50
Marital status
   Single 16.7% 17.8% 16.4% 14.0% 16.2% 12.8%
   Married/
   common-law
73.5% 72.1% 74.6% 72.5% 68.8% 75.0%
   Widowed 2.3% 2.5% 2.0% 3.5% 1.9% 3.6%
   Divorced 7.5%* 7.5%* 6.9% 9.9%* 13.0%* 8.6%
Education level
  Comprehensive school 13.4%* 15.3% 11.9% 20.0%* 20.3% 16.7%
   Vocational school 21.5%* 22.9% 21.3%* 26.6%* 29.4% 27.2%*
   High school 10.2% 10.2% 10.6%* 7.6% 11.8% 6.3%*
   College/institute 40.7%* 39.3%* 41.3%* 31.5%* 28.2%* 33.8%*
   University 14.1% 12.2% 15.0% 14.2% 10.5% 16.1%
Symptoms prior to meeting specialist (years)
   Mean 2.9 4.0 2.2 2.8 3.7 2.4
   Median 1.0 2.0 0.6 1.0 2.0 1.0
   Range 0-50 0-50 0-50 0-40 0-40 0-30
Family history of  IBD
   Yes 13.5%* 13.6%* 12.7%* 19.5%* 15.8%* 21.3%*
   No/no answer 86.5% 86.4% 87.3% 80.5% 84.2% 78.7%
CD = Crohn’s disease; UC = ulcerative colitis; IBD = inflammatory bowel disease
*indicates significant difference between the patient association and the Social Insurance
Institution samples
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The females were younger than the males (43 years vs. 45 years, p<0.001).  The mean
duration of the disease was 9.6 years (SD 7.8) and 277 (11%) had been diagnosed with
IBD at  least  20  years  earlier.   In  those  patients,  rates  of  CD and UC were  close  to  each
other (48% versus 50%).  The mean duration of the disease was shorter than that found in
the European study, for which almost three-quarters of the patients had been diagnosed
more than five years earlier.  This contrasts with the current study in which only 61% had
had the disease for over five years.  The study population included 190 patients who had
been diagnosed within a year and a majority (54%) of them had UC.  At least one first-
grade relative (parent, sibling or child) diagnosed with IBD was reported by 16% of CD
patients and by 14% of UC patients, which was slightly more than that observed in the
European survey (12% for the whole study population).  UC patients had received tertiary
education significantly more often than the CD patients (p=0.014). The reason for the
educational difference remains unexplained, and the level of education was not explained
by current activity of the disease or by the history of surgery.
The European study inquired as to whether the patients had been diagnosed by a
family physician, gastroenterologist, or other type of physician.  Due to the different
arrangement of the health care system in Finland, in the current study the patients were
asked whether they had been diagnosed by a health center physician or occupational
physician,  specialist (gastroenterologist, surgeon, or specialist in internal medicine), or by
any other type of physician.  A marked difference emerged in the way that diagnosis of
IBD was made in Finland and elsewhere in Europe.  In the European study three-quarters
of respondents were diagnosed by a gastroenterologist, whereas the percentage in the
current Finnish study for those diagnosed exclusively by a specialist was 96%.  No
difference in the rates could be seen for those patients diagnosed more than 20 years ago
and for those diagnosed more recently.  Moreover, 81% of the patients reported being
currently followed-up only by a gastroenterologist and for the remaining 19%, an
occupational or general physician took part in the therapy.  In Europe, a quarter of patients
reported at least some involvement of their family physician.
Both in the current study and in the previous European study patients reported long
delays before seeing a gastroenterologist after the emergence of the first IBD symptoms.
In our study, over 50% stated that they had experienced symptoms for a year or longer
before meeting a specialist, and 13% had waited for over five years.  For the CD group the
delay was particularly long, a mean 4.0 years (median 2.0 years) and 19% reported delay
of over five years.
5.2.1 Rates of surgery (I)
The rate of patients who had undergone surgery was high, 43%, for CD, and five patients
had undergone 10 or more operations due to their illness.  The percentage of surgery for
UC was considerably lower, 12%.  Rates of surgery were even higher in the European
survey for both CD (58%) and UC (14%).  Over a quarter of operated patients reported
serious postoperative complications in both surveys.  Furthermore, 4.6% of CD patients
and 1.4% of UC patients had a stoma after surgery and 8.5% of UC patients had an IPAA.
55
The rates of surgery are shown in Table 6. Although postoperative recurrence of
symptoms was reported by 67% of CD and 34% of UC patients, over 90% of CD patients
and 85% of UC patients stated that their quality of life had improved in the months
following surgery.  Similar rates could also be seen in the European study.
Those CD patients who had undergone surgery, experienced more disturbing
symptoms than did those treated conservatively.  After surgery, 22% of CD patients had
symptoms that greatly interfered with their leisure activities (13% in the non-surgery
group, p<0.001) and 19% had symptoms that greatly affected their ability to work (11% in
the non-surgery group, p<0.001).  In addition, UC patients with either stoma or IPAA felt
more disabled than did the patients who had not undergone surgery.














     Yes 42.6% 12.3% 2.5% 6.0%
     No/no answer 57.4% 87.7% 97.5% 94.0%
Postoperative situation
     Stoma 4.6% 1.4% 0.0% 0.0%
     IPAA 0.4% 8.5% 0.0% 1.2%
IBD=inflammatory bowel disease; IPAA= ileal pouch-anal anastomosis
5.2.2 Symptoms and extraintestinal manifestations (I)
The most common IBD symptoms reported were painful abdominal cramps, persistent or
recurrent diarrhoea, rectal bleeding, and fatigue.  Over half of the CD patients had suffered
from joint pain associated with their disease.  The percentage for UC was also high, 47%.
In the small group of patients with proctitis, fewer than 30% reported a history of joint
pain.
Comorbidity  with  ankylosing  spondylitis  was  reported  by  3.3%  of  patients,  with  the
highest percentage being in the CD group, 5.3%.  The results were similar for the
European study.
5.2.3 Frequency and impact of symptoms on daily life (I, II and III)
Impact of the disease on daily life was notable: 37% reported suffering from disturbing
symptoms weekly, as the percentage was 10% in the European study.  The symptoms
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greatly affected the ability to enjoy leisure activities in 17% of the patients, and in 14% of
the patients they greatly affected the person’s capacity to work.  In addition, many patients
reported inconvenience during leisure activities (51%) or at work (45%).  In the European
survey, the rate of patients who experienced difficulties at  work or during the pursuit  of
leisure activities was somewhat higher.  No significant gender or age difference was seen
for disease activity.  Patients recruited from the patient organization and from the national
register had no differences in disease activity as measured by the frequency of symptoms.
CD patients with a history of surgery reported a more active disease than did those who
had not undergone surgery (p=0.025) with 45% suffering from weekly IBD symptoms.
Table 7 shows the rates of symptoms associated with IBD.














Painful abdominal cramps 71.3% 64.3% 52.9% 70.6%
Persistent or recurrent
diarrhoea
76.5%       81.5% 60.3% 75.3%
Loss of appetite 39.8% 31.0% 17.4% 34.1%
Rectal bleeding 54.6%       83.4% 82.6% 71.8%
Weight loss 48.5% 44.7% 26.4% 43.5%
Fever 43.0% 30.9% 10.7% 32.9%
Joint pain 53.9% 46.5% 29.8% 54.1 %
Fatigue 54.7% 51.8% 30.6% 45.9%
Skin tags 22.4% 12.8% 14.9% 12.9%
Fistulas 19.9% 3.3% 2.5% 5.9%
Sores around the anal area 32.2% 26.2% 33.9% 28.2%
Adapted from: Haapamäki et al 2008
5.2.4 Current therapy (I, III)
Only 4.2% of the patients reported not taking any IBD medications at the time of the
survey, compared with as many as 18% in the European study.  Two-thirds reported a
previous intake of corticosteroids and over one-fifth were taking corticosteroids at the time
of the survey.  The current use of immunomodulators was reported by 33% of all patients,
as the rate for CD was significantly higher 44% (p<0.001).  The numbers are higher than
in the European survey, which found that 31% of CD patients and 19% of UC patients
were receiving immunomodulators.  At the time of the first mailing of the questionnaires
(in 2006), infliximab was the only biological medical treatment indicated for IBD.  A few
patients reported that they were receiving adalimumab off-label.  Current or previous use
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of biologicals was reported by 193 patients (8.0%) in the patient association sample, and
over 80% of them had CD.  The percentage was lower, 3.9%, for the national register
sample, mainly due to different disease distribution (CD 26%, UC 59%).
5.2.5 Patient satisfaction (I)
Despite the burden of symptoms on daily life, the great majority (93%) of patients
expressed satisfaction with their current treatment and only 1.4% were very dissatisfied.
Dissatisfaction was at least partly related to treatment resistant disease activity, as 60% of
the very dissatisfied subjects had weekly symptoms of IBD. When asked about the impact
of different therapies (steroids, immunomodulators, biologicals and surgery) on the quality
of life, all therapies were associated with at least some level of increased quality of life
during the months following treatment for over 70% of the patients.  Those consulting a
specialist during follow-up, expressed satisfaction more often with their current therapy
than those being followed-up by general practitioners or occupational doctors (94% versus
89%, p=0.02).
The level of satisfaction was higher in the current study than that found in the previous
European EFCCA study, in which only 76% expressed satisfaction with their current
treatment.
The majority of the patients (60%) stated that their doctors had never asked about the
impact of their IBD symptoms on their quality of life.
5.3 Comorbidity (IV)
Reimbursements for chronic diseases in addition to IBD were observed in 29% of the
patients.  On the other hand, 0.7% of the control subjects, who were matched for age,
gender and hospital district, had reimbursement for IBD, a percentage that was
proportional to the actual prevalence of IBD in the population (Statistical Yearbook of the
Social Insurance Institution 2008).
Significant increases in frequencies of connective tissue diseases (p<0.001), asthma
and chronic obstructive pulmonary diseases (p<0.001), pernicious anaemia (p<0.001) and
coronary  heart  disease  (p=0.004)  were  associated  with  IBD.  No  differences  in  the
occurrence of malignant diseases were seen. Malignancies were relatively rare for both
IBD patients and for the controls, with a prevalence of less than 1%.  The most prevalent
comorbid diseases are presented in Table 8.
Females with IBD in particular appeared to be at increased risk of CHD (1.6-fold,
p=0.014) compared with their peers in the general population.  The comparable CHD risk
of the male IBD patients was only just significantly increased (p=0.046), but it was still
over two-fold compared to the female IBD patients (1.4% versus 3.4%, p=0.043 after
controlling for age).  For those patients diagnosed with IBD at over 50 years of age
(n=299, current mean age 64 years), the CHD prevalence was only just significantly
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higher than for their peers in the general population (9.7% versus 6.0%, p=0.045).
Patients with both IBD and CHD were slightly, but non-significantly, younger than
patients with only CHD (64.5 versus 66.2 years).  IBD had been diagnosed earlier than
CHD in 66% of the cases.
Those with the most active disease (weekly symptoms) had a higher risk of having
other chronic diseases in addition to IBD, than did those patients with less active disease
(p=0.028 between the groups). IBD activity was especially related to prevalence of CHD
(p=0.030), chronic cardiac insufficiency (p=0.030), pernicious anaemia (p=0.022),
epilepsy (p=0.010), and glaucoma (p=0.007).
















0.3% 0.5% 0.4% 0.7%
Connective tissue diseases,
rheumatoid arthritis




4.3%* 7.1%* 7.0% 7.3%
Chronic hypertension 7.5% 8.1% 8.3% 7.7%
Chronic coronary heart
disease
1.4%* 2.2%* 2.2% 2.0%
Chronic arrhythmias 0.6% 0.6% 0.6% 0.5%
Diabetes mellitus 2.6% 2.3% 1.7% 2.3%
Thyroid insufficiency 1.7% 1.9% 1.6% 2.0%
Pernicious anemia 0.2%* 4.1%* 10.3%† 0.3%†
Multiple sclerosis 0.2% 0.1% 0.0% 0.1%
Epilepsy and comparable
convulsive disorders
1.4% 1.1% 0.9% 1.1%
Severe psychotic and other
severe mental disorders
2.3%* 1.6%* 1.7% 1.4%
Glaucoma 0.7% 0.9% 0.9% 0.9%
Cancer or leukemia 0.9% 0.8% 0.9% 0.6%
*,† significant difference between groups (controls/IBD patients, or CD/UC); IBD, inflammatory
bowel disease; CD, Crohn’s disease; UC, ulcerative colitis
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5.4  IBDQ scores (II, III, IV)
Of all the patients, 63 had filled in the IBDQ inadequately for calculating the scores, and a
further 171 patients had left single IBDQ questions unanswered. The total IBDQ scores
ranged from 43 to 224 in the current study, as the possible range is 32-224.  The mean
total score was 163 (SD 35.1).  As in many earlier studies, females had significantly lower
scores (161, SD 34.8) than did males (168, SD 35.5) (p<0.001), and males had higher
scores for all  dimensions except for social  functions.   However,  the medians of the total
scores were closer to each other, 166 in females and 168 in males.  The sample taken from
the patient association scored significantly worse (mean 163) than that of the national
register (mean 170) (p<0.001).
Those who had been diagnosed within the last five years, scored significantly lower
than those with a longer-lasting disease, and particularly low scores were seen in those
who had been diagnosed during the previous year (154, SD 34.8, p<0.001).  Older age
also affected the scores, and patients over 50 years of age had significantly lower scores
than did younger patients, 159 (SD 35.4) versus 165 (SD 34.9) (p<0.001).
There was a statistically significant difference in the scores between UC and CD, but
the difference disappeared, when the groups were adjusted for disease activity.
Disease activity had a great impact on the IBDQ scores as shown in Figure 3.  The
mean score was 136 (SD 32.1) for patients with weekly symptoms, compared to 177 (SD
26.8) for those who suffered from IBD symptoms only occasionally (p<0.001).
Satisfaction with current treatment also reflected the scores, and for those who expressed
satisfaction, the mean score was 166 (SD 33.4) compared to 124 (SD 34.7) for dissatisfied
subjects (p<0.001).  No significant differences existed between patients who were being
followed-up by specialists and those who were being followed-up by occupational doctors
or general practitioners.
 The history of surgery impaired IBDQ scores in this survey, and a mean IBDQ score
was 158 (37.2) for those who had undergone surgery compared to 166 (SD 33.7) for non-
surgical patients (p<0.001).  No significant post-surgical difference between UC and CD
was detected.  In general, the patients with IPAA (156, SD 40.8) or stoma (153, SD 36.1)
had even lower scores compared to all surgical patients.
Comorbidity with other chronic reimbursed diseases was also associated with
significantly impaired IBDQ scores.  As IBD patients without other chronic diseases had a
mean IBDQ score of 168 (SD 34.3), those who had any other reimbursed disease scored
157 (SD 36.2) (p<0.001).  Patients with hypertension, pernicious anaemia and severe
mental disorders in particular had lower scores than average (p<0.001).
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Figure 3. Mean 15D and Inflammatory Bowel Disease Questionnaire (IBDQ) scores and







































Possible range is 0 to1 for the 15D and 32 to 224 for the IBDQ.  A higher score indicates
better quality of life.
Figure adapted from: Haapamäki et al 2010
5.5 15D scores (III, IV)
More than three 15D questions were unanswered by five respondents who were therefore
omitted from the analyses.  Single questions were left unanswered by some respondents,
and the total number of unanswered questions was 188.  The question that considered
sexual activity had been left unanswered by 64 respondents.  The range of 15D scores was
0.30-1.00, with a mean of 0.87 (SD 0.097).  A ceiling effect was observed as 6.2% of
patients scored 1.00 (perfect health).  Disease activity was strongly associated with the
score even after differences in scores were adjusted for age, gender and diagnosis
(p<0.001).  Figure 4 shows the 15D profiles in groups of different disease activity.
Gender or disease type had no significant impact on the scores but older age was related to
lower scores. Both groups of newly-diagnosed patients and patients with a long-lasting
disease had lower scores even after adjusting for age.  After surgery, the mean score was
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Figure 4. 15D profiles by frequency of inflammatory bowel disease symptoms.
Figure adapted from: Haapamäki et al 2010
significantly lower than in patients who had not had surgery, 0.85 versus 0.88 (p<0.001)
and it was 0.84 for stoma patients. No significant differences emerged between patients
who were being followed-up by specialists and patients who were being followed-up by
occupational doctors or general practitioners. Again, patient association subjects had
significantly lower scores than other patients (0.87 versus 0.88) (p=0.002).
As observed with IBDQ, comorbidity with other chronic conditions was associated
with impaired 15D scores.  Suffering from any other chronic reimbursed disease impaired
significantly the 15D score (p<0.001).  Most strikingly this was seen for hypertension,
obstructive pulmonary diseases and severe mental disorders (p<0.001).
The 15D score appeared to be strongly related to the total IBDQ score (Pearson’s
correlation coefficient of 0.733, p<0.001), which indicates its applicability for the
measurement of HRQoL in IBD patients (Figure 3).
The age and gender-standardized population sample had significantly higher scores for
all  dimensions,  except  for  speech  (Figure  5).   Not  even  the  IBD  patients  who  reported
symptoms  less  often  than  monthly  could  achieve  the  15D  level  of  the  controls  (mean
scores 0.902 for IBD versus 0.927 for controls).  Differences in 15D scores in addition to
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Figure 5. 15D profiles of the study group and of an age- and sex-standardized sample












































































General population Study subjects
All differences are significant except for speech (mobility, p=0.023; vision, p=0.003;
eating, p=0.032; for other dimensions, p<0.001).
Figure adapted from: Haapamäki et al 2010
Table 9.  Comparison  of  results  of  the  patient  association  and  of  the  Social  Insurance












Rate of surgery 25% 16% <0.001
IBDQ score 163 170 <0.001




Frequency of CHD 1.9% 3.4% NS*




IBDQ = Inflammatory Bowel Disease Questionnaire; CHD = coronary heart disease; NS
= not significant; *= analyzed after controlling the groups for age
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6 Discussion
6.1 Patients and methods
At the end of year 2007, the Social Insurance Institution register comprised 30 051
patients (both children and adults) who were eligible for reimbursement for IBD
medication (Statistical Yearbook of the Social Insurance Institution 2008).  Therefore, the
study subjects represented over 9% of Finland’s IBD population.  The questionnaires were
mailed only once, and no reminders were subsequently sent.  Nevertheless, the response
rate was still 57% (63% for members of Crohn and Colitis Association), which can be
considered as satisfactory.
The Social Insurance Institution register comprises mainly patients with current or
earlier IBD medication, and for example UC patients who end up to colectomy very soon
after the diagnosis may not have claimed for reimbursement for their IBD medication.
Nonetheless,  the  reimbursement  register  can  be  considered  as  very  representative  of  the
whole IBD population.
Most of the surveyed patients were members of the patient association. The possible
differences between members and non-members are not fully known, but being a member
may indicate that the subject has found his/her disease problematic in some way.  The
patient association members had significantly lower HRQoL scores than those of the
patients who were recruited from the national register, although no differences in disease
activity were detected between them and the patients recruited from the national register.
It  should  be  noted,  however,  that  the  rating  of  disease  activity  was  based  solely  on  the
subjective information obtained from the respondents, not on clinical or endoscopic
scores.  Consequently, the ‘activity of the disease’ as experienced by the respondent does
not  necessarily  equal  that  of  the  true  activity  of  the  disease.   Moreover,  the  division  of
activity into three levels according to frequency of symptoms is robust.  Nevertheless,
getting more specific data would have been difficult with self-administered questionnaires.
Due to confidentiality regulations, no information about the non-respondents was
available.  Returning of the questionnaires was optional, and it is possible that those who
returned the questionnaire may have felt more disabled due to their disease, or may have
been more aware of issues concerning HRQoL.  Some respondents did not answer all the
questions in the questionnaire.  At less than 1%, the number of unanswered questions was
relatively small, however.
No significant difference in the prevalence of IBD between genders has been evident
in epidemiological surveys (Loftus 2004, Vind et al 2006), but due to the gender
distribution of the patient association, our sample had a predominance of females.  In the
sample obtained from the national register, 52% of the respondents were female, which
indicates no significant differences in response rates between the sexes.  The study
population included patients of different age groups and from different parts of the
country, who lived in either a city and or in rural areas, thus the samples can be considered
representative of the IBD population in Finland.
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The postal survey design of the survey had its advantages and disadvantages.  We
reached patients from all over the country by mailing the questionnaires, and the patients
were followed-up in various hospitals instead of a single or a few centers.  On the other
hand, the only information about the diagnoses, symptoms and therapies came from the
patients themselves.  The Social Insurance Institution register included systematic data on
exact diagnoses for those diagnosed in 2000 and later.  However, most patients appeared
to be well aware of their diagnosis and a few patients who were unsure of the diagnosis
were classified into the group of unspecified colitis, which was mostly not used for
statistical calculations because of its small size.
The study population included 58 subjects with a stoma. In all respects, the IBDQ
questionnaire is not ideal for them, as it includes questions about frequency of bowel
movements  and  continence.   Nevertheless,  the  views  of  stoma  patients  were  still  of
importance, so they were included in the analyses.  The IBDQ has also been used in stoma
patients in other surveys (Nordin et al 2002, Camilleri-Brennan et al 2003, Watanabe et al
2006).
6.2 Symptoms and therapy (I, II, III)
The time from first IBD symptoms to diagnosis was strikingly long in our study, as over
half of the respondents reported symptoms for a year or longer before having an
examination by a specialist.  The delay was especially long for CD patients, and exceeded
the time intervals reported in earlier studies (Vind et al 2006).  As there were a few very
long reported delays, the median is probably a more informative parameter of the actual
situation.  It is noteworthy, that the time before diagnosis was not significantly shorter for
the patients diagnosed during the past 10 years.  This finding suggests that despite the new
diagnostic tools and an increased number of gastroenterologists, a suspicion of CD does
not always arise because of the sometimes obscure or indefinite symptoms.  Many of the
patients who reported long delays before meeting a gastroenterologist, at the time of the
survey lived outside big cities, and sometimes in areas where only a few
gastroenterologists or other specialists are available.  After diagnosis, most of the patients
were in the follow-up of a specialist, however.  In many cases, a specialist took part in the
therapy in addition to the family or occupational doctors.
As IBD is a relatively rare disease that in many cases needs immunosuppressive
therapy and regular laboratory and endoscopic examinations, it is logical that specialists
be involved in treatment decisions.  Even so, it is unclear, whether being in the follow-up
under the care of a specialist improves HRQoL.  The problem in interpreting this is that
patients with the most severe disease usually remain under the care of specialists, whereas
patients with non-problematic disease course are usually followed-up in primary care.  In
an UK community based study, being under specialist care was related to lower IBDQ
scores (Rubin et al 2004).  In the current study, patients who were followed-up at least in
part by a specialist expressed significantly more often satisfaction with their current
65
therapy than those who were solely followed-up by occupational or family doctors.
Despite this, no differences appeared in 15D or IBDQ scores between the groups.
Differences in treatment practices of IBD exist between different countries (Odes et al
2006).  Compared to the earlier European EFCCA survey, Finnish patients used 5-ASA
medication more frequently than did patients in the earlier study.  5-ASA appears to have
a protective effect from CRC for both UC and colonic CD (Munkholm 2003, Winther et al
2004) but it has been rated no more effective than a placebo for active ileal CD (Dignass
et al  2010).  In the Finnish Current Care treatment guideline published in 2005, it is stated
that 5-ASA is still a standard therapy for CD, which partly explains the common use of the
medication.  The use of immunomodulative and biological therapy was also more
common in the current study, whereas rates of surgery for the CD patients were lower.
Most patients reported an improved quality of life shortly after surgery, which is
indicative of succesful patient selection for surgery.  After the favourable situation
immediately  following  surgery,  recurrences  of  symptoms  were  common  in  the  long  run
for  both  CD  and  UC  patients.   Maintaining  postoperative  remission  in  CD  remains  a
challenge, even though novel therapies have reduced the rates of postoperative
recurrencies (Regueiro et al 2009, Dignass et al 2010, Papay et al 2010).  It has been
reported that after IPAA surgery, chronic pouchitis and other pouch-related problems are
common and can lead to the need for permanent ileostomy in 5% of the patients (Lepistö
et al 2002, Cohen et al 2005).
     Differences  in  treatment  practices  of  IBD  in  different  parts  of  Finland  have  been
examined, as well. The rates of surgery varied somewhat between different university
hospital districts, but otherwise treatment modalities, and also patient satisfaction were
found to be equal (Haapamäki et al 2010).
     The burden of IBD symptoms on the lives of patients and on society as a whole is
remarkable.  In spite of most patients being under the care of specialists, over one-third of
the patients suffered from weekly IBD symptoms and many patients stated that the
symptoms affected their capacity to work.  A cost-analysis was not included in our survey,
but in earlier surveys, a great amount of direct (hospitalizations, medications and surgery)
and indirect costs (lost workdays, restricted activity days and early retirements) have been
related to IBD, and these costs are higher in those with a more active disease (Gibson et al
2007).  The mean annual costs of IBD vary considerably from country to country
depending on the arrangement of therapy.  In a European study, mean annual costs were
1524€ for UC and 2548€ for CD (Odes et al 2006).   In  the  US,  the  annual  costs  were
higher, $8265 ( 6140€) for CD and $5066 ( 3764€) for UC in 2008, and hospitalizations,
medications and outpatient care were all attributable for about one-third of the costs
(Kappelman et al 2008).  Novel therapies, such as biological medications, have been
found to improve the HRQoL and reduce resource use (Rubenstein et al 2002, Hanauer et
al 2002) at least in the short term.  Maintenance therapies that last under four years have
been found to be cost-effective in selected CD patients (Bodger et al 2009).  The
additional costs caused by using biological medications in long maintenance therapies
may exceed the conventional benchmarks for affordability.  The problem with these
models is the lack of  real-patient data and lack of data of effect of infliximab on the long-
term course of IBD (Bodger 2005).
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6.3 Comorbidity (I, IV)
The self-reported rate of IBD patients for ankylosing spondylitis was 22 times higher and
that of rheumatoid arthritis about three times higher than the corresponding values in the
general population (Kaipiainen-Seppänen et al 1997, Aho et al 1998).  Furthermore, the
frequency of joint pain was remarkable.  In addition to the impairment of HRQoL caused
by these complaints, there are other problems related to joint and axial pain associated
with  IBD.   The  therapy  of  joint  or  axial  pain  in  IBD  patients  may  be  problematic.
Although the question about whether NSAIDs cause exacerbations of IBD is still unclear,
in some cases at least their gastrointestinal and other side-effects can be detrimental to
IBD patients (Feagins and Cryer 2010).
According to reliable data obtained from the Social Insurance Institution register, the
prevalences of connective tissue diseases, asthma and obstructive pulmonary diseases,
CHD, and pernicious anaemia were significantly higher for IBD patients than for their
controls.  However, regarding the diagnosis of pernicious anaemia in IBD patients, many
of these patients are in fact CD sufferers who have undergone ileal resections that have led
to a reduction in the absorption of vitamin B12.
Females  with  IBD appeared  to  be  at  increased  risk  for  CHD compared  to  their  non-
IBD counterparts.  The comparable risk for CHD in IBD males was only just significantly
increased,  but  was  still  more  than  two-fold  compared  to  female  IBD  patients,  which
indicates the much higher overall risk for CHD in males.  In the national reimbursement
register, 33 035 males aged 15-64 years have CHD, whereas the number is 9968 in
females of the same age (a 3.3-fold difference).  The difference between the older age
cohorts is much smaller (Statistical Yearbook of the Social Insurance Institution 2009).
IBD may contribute to the preterm development of CHD, although in this study no
significant age difference was found between patients with both IBD and CHD and those
patients with CHD alone.  The use of acetylsalicylic acid preparations may have induced
gastrointestinal bleeding leading to the discovery of earlier unsymptomatic or quiescent
IBD in those patients initially diagnosed with CHD.   Long-lasting and active IBD was a
risk factor for CHD in both sexes.  Chronic inflammation is suspected to accelerate
atherosclerosis, and increased CHD risk has also been found in other inflammatory
disorders, such as in rheumatoid arthritis (Sattar et al 2003, Snow and Mikuls 2005).
However, in some studies no relationship between chronic inflammation and
atherosclerosis has been determined after the appropriate corrections for known risk
factors (Hansson 2005, Hamirani et al 2008).  It is unfortunate, that no data on the
smoking habits (or on lipid values) of our study subjects were available due to nature of
the study.
The accuracy of IBD diagnoses in elderly patients with CHD needs to be considered.
Ischaemic colitis has been suspected to be misdiagnosed as IBD on certain occasions
(Brandt 2005).  In such a case, one would expect the rate of CHD to be significantly
higher  in  those  patients  diagnosed  with  IBD  in  their  late  middle  age  or  in  old  age.
However, no convincing evidence of this was found in our study.
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6.4 Health-related quality of life and patient satisfaction (I, II, III,
IV)
Disease activity was found to be the most important factor that predicted HRQoL, as noted
in earlier studies (Irvine et al 1994, Casellas et al 2002, Guthrie et al 2002, Hjortswang et
al 2003).  The history of surgery was also related to both generic and disease-specific
lower scores, which reflected the frequent postoperative recurrence of the disease and high
reported rates of postoperative complications in study patients.  The observed HRQoL of
IPAA and stoma patients was lower than those reported by earlier surveys (Camilleri-
Brennan et al 2003, Berndtsson et al 2007).  Nevertheless, one must remember that those
who had no problems may have considered it unnecessary to return the questionnaire.
Disease activity probably also explains the lower HRQol scores for the newly-diagnosed
patients.  Another study on paediatric patients showed a similar result (Otley et al 2006),
whereas in some other surveys a short disease duration was not associated with impaired
HRQoL (Han et al 2005).
The differences in IBDQ scores of patients who receive different medications are
mostly explained by the severity of the disease. Even the most effective and modern
pharmaceutical preparations can not completely prevent the negative impact of disease on
HRQoL.  When compared to a placebo or to other medications, most of the medications
currently in use have been shown to improve HRQoL (Feagan et al 2007a, Irvine et al
2008, Bastida et al 2010).
Despite the frequency of disturbing IBD symptoms, the great majority of patients
expressed satisfaction with their current treatment.  More patients in the current study
were satisfied with their treatment than were found the in the other European countries
(Ghosh and Mitchell 2007).  The separate rates for each of the seven participating
countries in that study have not been published.  The sociodemographic characteristics of
the patients, the local health care systems, and other conditions vary within and between
different European countries, which is probably the main reason for the differences.
Other reasons are the variation in accessibility to treatment and also the actual differences
between  treatment  practices  among  the  countries.   However,  the  level  of  satisfaction
expressed by the patients is indicative of good treatment practices in Finland.
The fact that 60% of the patients reported that their doctor never asked them about the
impact of IBD symptoms on the quality of life is striking.   Health care personnel often
focus on reducing the actual disease symptoms, which indeed is one of the most important
aspects in improving HRQoL.  However, there are other important factors of HRQoL,
such as psychological problems or comorbidity with other diseases, and their impacts can
be difficult to detect by only looking at the patient’s symptoms and objective medical
findings.
In this survey, females reported worse disease-specific HRQoL than did males.  This
gender difference is a common finding in HRQoL studies, and the reason for it is mainly
unresolved (Hunt and Annandale 1999, Guallar-Castillón et al 2005, Gallicchio et al
2007).  Disease activity per se was not different between the sexes, but it is possible that
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females experience symptoms of IBD as being more awkward and disturbing than do
males.
15D appeared to be a feasible and applicable instrument for evaluating HRQoL in IBD
patients.  It had a ceiling effect of 6.2%, which is comparable or better than in other
generic HRQoL tools.  In a Finnish population sample, EQ-5D had a ceiling effect of 47%
compared to 15% for 15D, which is indicative of the better discriminative power of 15D
(Saarni et al 2006).  15D scores were more impaired with increasing age, which has also
been reported in other 15D studies, and in studies that used other generic HRQoL
instruments (Saarni et al 2006, Hopman et al 2009, Sørensen et al 2009).  When compared
to other studies of chronic conditions, the 15D scores of IBD patients have been similar to
those of patients with epilepsy, diabetes-related complications, or anxiety (Stavem 1998,
Hahl et al 2002, Pirkola et al 2009), but lower than those of patients who had undergone
renal transplantation (Yildirim 2006).
6.5 Patient groups at risk of HRQoL impairment
The  most  striking  impairment  in  HRQoL  was  seen  in  those  patients  with  active,
symptomatic disease.  In addition, newly-diagnosed patients, many of whom were still
having frequent IBD symptoms, and also older patients with increased rates of comorbid
diseases had lower HRQoL scores.  Perhaps surprisingly, HRQoL was impaired in
patients who had undergone surgery, a feature very clearly observed in both CD patients
and in UC patients after IPAA surgery.  Similar to many other HRQoL studies, females in
general had lower IBDQ scores than males.  However, in this study, the generic 15D
scores did not differ significantly between the sexes.  Patients with comorbid diseases, or
with extraintestinal manifestations of IBD, also had impaired HRQoL.
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7 Conclusions
IBD is a chronic, relapsing disease that often occurs at a young age.  It is common for IBD
patients  to  have  symptoms  that  affect  leisure  activities,  work  and  their  HRQoL.  The
frequency of symptoms was higher in Finnish IBD patients in this current study than in
patients recruited in an earlier European study.  Nevertheless, Finnish patients found their
symptoms to be less disturbing, and the patients were more satisfied with their current
therapy compared to the patients of the other European countries.
HRQoL has become an essential outcome of health care, though no gold standard for
HRQoL exists.  Generally, the use of both generic and disease-specific HRQoL
instruments  has  been  considered  optimal  in  HRQoL  assessment.   In  this  study,  both
generic 15D and disease-specific IBDQ instruments were used.
Disease activity, as experienced by the patient, was the most important factor related to
HRQoL.  Of the demographic factors, older age, comorbid diseases, and female gender
reduced the IBDQ scores.  Other patient groups at risk of lower HRQoL were those with a
newly-diagnosed disease and those with a history of surgery, especially after having had a
stoma or an IPAA operation.
The generic 15D instrument appeared to be a feasible instrument for estimating the
level of HRQoL in IBD.  The 15D scores were significantly lower for IBD patients than
for the general population sample.  Active disease, older age and a history of surgery were
associated with lower scores. IBDQ and 15D scores were strongly correlated in IBD
patients, an observation that justifies the use of 15D as a fast and easily applied
questionnaire for examining HRQoL of IBD patients.
The risks of many other chronic diseases, such as CHD, connective tissue diseases,
asthma and chronic obstructive pulmonary diseases, were increased in IBD, and the
comorbidities had a negative impact on the HRQoL.  The increased prevalence of CHD in
IBD encourages more efficacious management of other possible underlying cardiovascular
risk factors (e.g. smoking and hypertension) and the inflammatory activity of IBD.  The
increased risk of preterm cardiovascular disease should be borne in mind especially in
females.  Furthermore, health-care personnel should be aware of the negative impact of
comorbid diseases on the HRQoL of IBD patients.
HRQoL assessment  helps  to  identify  patients  who need  special  support.   With  novel
IBD therapies, symptoms and relapse rates of IBD are fewer for many patients.  In such
patients, the emphasis in examining the impact of the disease on their HRQoL should be
directed at other areas in contrast to the approach that should be taken for patients with the
active disease.  Even when quiescent, the disease may have marked adverse impacts on the
lives of the patients.  Patients with an inactive disease often worry about the side-effects of
medication, body-image issues, and the increased risks of surgery or of having cancer.
The emphasis for patients with the inactive disease should be as much on addressing these
issues than on easing individual IBD symptoms, especially in those patient groups that are
prone to a low HRQoL.  Correspondingly, for patients with the active disease, the main
emphasis should be on ameliorating IBD symptoms and on improving various aspects of
general well-being. These could be realised by therapeutic interventions to achieve
improvement in both the patient’s physical condition and his or her quality of life.
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